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SUMMARY 
Cell surface proteins are of ongoing interest in several areas of research and development. 
This can be attributed to the fact that in addition to the dynamic behavior of the membrane 
which affects the nature and properties of these proteins, cell surface proteins are involved in 
important cellular activities such as signal transduction, immune response, cell adhesion and 
communication. To elucidate their structure and function several cell surface protein labeling 
strategies have been developed in recent years. These strategies in conjunction with 
fluorescence microcopy techniques provide a powerful tool for studying membrane proteins.  
Split inteins have established themselves in the field of biochemistry and molecular biology 
as influential workhorses for the manipulation of proteins. This is evident from the numerous 
biotechnological applications where they have been utilized. Split inteins (both artificially 
created in the laboratory as well as naturally occurring) are expressed as separate fusion 
proteins and undergo protein splicing in trans. This autocatalytic protein trans-splicing (PTS) 
event requires the intein halves to associate with each other, resulting in the formation of an 
active complex. Consequent removal of the split intein halves joins the flanking extein 
sequences with a native peptide bond.Naturally split inteins confer certain advantages in terms 
of solubility and folding to the intein fusion proteins as they have evolved to splice two 
protein halves. 
In this work, the ability of the naturally split DnaE intein from Nostoc punctiforme for 
labeling cell surface proteins has been demonstrated. The superior splicing properties of this 
intein make it an ideal candidate for this purpose. Using confocal microscopy and western 
blots it could be shown that intein halves fused to non-native exteins can be expressed on the 
extracellular surface of mammalian cells and efficiently labeled. The PTS reaction could be 
carried out on the surface of live cells at the physiological temperature of 37 °C in serum free 
cell culture media within minutes. The reaction was independent of the presence of a reducing 
agent and the choice of membrane anchor (transmembrane domain or GPI). It was however 
affected by the intein half being expressed on the cell surface as well as the length of the 
linker region between the intein half and the transmembrane anchor. The extein sequences 
were also shown to play an important role in the splicing reaction on the cell surface. In 
conclusion, the conducted studies establish this strategy as a fast and efficient means for 
labeling cell surface proteins. It is expected to be beneficial for the manipulation of membrane 
proteins as well as preparation of GPI-anchored proteins. 
In addition, an attempt has been made in this work for labeling cell surface proteins using the 
PCP-domain and performing PTS on the surface of quantum dots for labeling any POI.  
 
 
 
 
IV 
ZUSAMMENFASSUNG 
Oberflächenproteine stellen ein Forschungs- und Entwicklungsgebiet von anhaltendem 
Interesse dar. Dies lässt sich auf die Tatsache zurückgeführten, dass zusätzlich zu dem 
dynamischen Verhalten der Plasmamembran, die das Verhalten und die Eigenschaften von 
Proteinen beeinflusst, Zelloberflächenproteine in wichtige zelluläre Vorgänge involviert sind. 
Zu diesen zählen u.a. die Signaltransduktion, Immunantwort, Zelladhäsion und 
Zellkommunikation. Zur Aufklärung von Stuktur und Funktion von Oberflächenproteinen 
wurden in jüngster Zeit einige Markierungsstrategien entwickelt. In Verbindung mit der 
Technik der Fluoreszenzmikroskopie stellen diese Strategien ein leistungsstarkes Werkzeug 
zur Erforschung von Membranproteinen dar. 
Gespaltene Inteine haben sich in den Gebieten der Biochemie und Molekularbiologie als 
effizient Werkzueg zur Manipulation von Proteinen etabliert, was anhand ihrer vielfältigen 
biotechnologischen Anwendungen ersichtlich wird. In diesen Fällen werden entweder die 
artifiziell im Labor erzeugten oder natürlich vorkommenden gespaltenen Inteine als separate 
Fusionsgene exprimiert und anschließend die Proteinspleißreaktion in trans durchgeführt. 
Dieser autokatalytische Vorgang des Protein-trans-Spleißens (PTS) erfordert zunächst die 
Assoziation der Inteinhälften und die Bildung des aktiven Komplexes. Anschließend werden 
während der Entfernung der Inteinhälften die flankierenden Exteinsequenzen in einer nativen 
Peptidbindung miteinander verknüpft. In Bezug auf Löslichkeit und Faltung der 
Inteinfusionsproteine besitzen natürlich gespaltene Inteine einige Vorteile, da sie sich zur 
PTS-Reaktion von gespaltenen Proteinen evolviert haben.  
In dieser Arbeit wurde des natürlich gespaltene DnaE-Intein aus Nostoc punctiforme 
erfolgreich zur Markierung von Oberflächenproteinen verwendet. Die ausgezeichneten 
Spleißeigenschaften dieses Inteins machen es zu einem idealen Kandidaten für diesen Zweck. 
Unter Verwendung von Konfokalmikroskopie und Western Blot Analyse konnte gezeigt 
werden, dass die mit nicht-nativen Exteinen fusionierten Inteinhälften exprimierten und auch 
effizient auf der extrazellulären Oberfläche von Säugerzellen markiert werden konnten. Bei 
physiologischer Temperatur von 37 °C und in serumfreiem Zellkulturmedium lief die PTS-
Reaktion auf der Öberfläche von lebenden Zellen innerhalb von Minuten ab. Dabei war die 
Reaktion weder von der Anwesenheit reduzierender Agenzien noch von der Wahl des 
Membranankers (Transmembrandomäne oder GPI) abhängig. Allerdings wurden sie einerseits 
von der Art der auf der Zelloberfläche exprimierten Inteinhälfte beeinflusst und andererseits 
von der Länge der Linkerregion zwischen Inteinhälfte und Transmembrandomänenanker. Des 
Weiteren nahmen die verwendeten Exteinsequenzen eine besondere Rolle in der 
Spleißreaktion auf der Zelloberfläche ein. Aufgrund der durchgeführten Studien konnten die 
entwickelte Strategie als eine schnelle und effiziente Methode zur Markierung von 
Oberflächenproteinen etabliert werden. Es ist davon auszugehen, dass diese bei der 
Manipulation von Membranproteinen und zur Herstellung von GPI-verankerten Proteinen 
vorteilhaft sein wird. 
In einem weitern Teil der Arbeit wurde versucht Zelloberflächenproteine mit Hilfe der PCP-
Domäne zu markieren. Weiterhin erfolgten Experimente zum Protein trans-Spleißen auf der 
Oberfläche von Quantum dots um beliebige Proteine von Interesse zu markieren.
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1 INTRODUCTION 
 
Integral membrane proteins carry out several vital functions across cell membranes such as 
signal transduction, material transport and intercellular communication.
[1]
 Investigations of 
such membrane proteins in living cell membranes is important because biomembranes are 
heterogeneous and dynamic which affects their behavior. Visualization of membrane proteins 
in living cell membranes is essential for observing the dynamic behavior of proteins such as 
endocytosis and also allows detection of conformational changes and monitoring protein-
protein interactions by FRET which detects changes in distance and/or orientation of different 
fluorophores having a spectral overlap. Site-specific labeling of proteins is a key technique for 
the detection of a target protein by fluorescence microscopy. Surfaces of cultured cells are 
freely accessible to chemical treatment and therefore labeling cell surface proteins with 
fluorescent molecules appears as an attractive strategy to equip them with probes that allow 
for their functional characterization.
[2]
 
In this work, a split intein mediated approach (protein trans-splicing/PTS) for site-specific 
labeling of cell surface proteins using the Npu DnaE intein is presented. Two genes are 
known to code for the α-subunit of the DNA polymerase III (DnaE) protein in Nostoc 
punctiforme. One gene codes for the N-terminal half of the protein (DnaE
N
/Ext
N
) which is 
succeeded by the N-terminal half of an in-frame intein sequence (Int
N
). The second gene 
codes for the C-terminal half of the intein (Int
C
) followed by the C-terminal half of the protein 
(DnaE
C
/Ext
C
). The “split” intein sequence is not a part of the functional DnaE protein and is 
removed by a post-translational autocatalytic mechanism inherent to the intein sequence 
which ligates the two halves of the DnaE protein with a native peptide bond. Iwai and 
coworkers demonstrated that the intein retained its catalytic character when the DnaE 
sequences were replaced with non-native extein sequences.
[3]
 
Theoretically, if a transmembrane protein is fused to one half of the split intein with the intein 
part facing the extracellular environment and is expressed on the surface of mammalian cells, 
then the exogenous addition of a recombinantly expressed and purified protein containing a 
desired modification fused to the other split intein half will lead to the intein fragments 
recognizing and associating with each other. Autocatalytic removal of the intein sequences 
will then result in a modified/labeled cell surface protein (Figure 1).
[4]
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Figure 1 Schematic representation of cell surface protein labeling using the split-intein mediated 
approach. The Int
C
 is fused to the N-terminus of a membrane protein (Ext
C
) and expressed on the 
surface of mammalian cells. The Int
N
 is fused to the C-terminus of the desired protein of interest or a 
peptide sequence (Ext
N
) and is recombinantly expressed in E.coli. In the first step, the purified Int
N
 
fusion protein is added to the surface of cells expressing the Int
C
 fusion protein. In the second step, the 
intein halves are expected to recognize each other and associate non-covalently, form an active intein 
conformation and catalyze a protein trans-splicing reaction. Ext
N
= N-Extein sequence, Ext
C
= C-extein 
sequence, Int
N
= Intein N-terminal half, Int
C
= Intein C-terminal half, PTS = Protein trans-splicing 
 
Our view of the simple „central dogma‟ of biology (Figure 2) is constantly challenged by 
rapidly evolving evidence for editing at the protein level including proteolytic cleavage of 
polyproteins, protein autoprocessing, non-ribosomal addition of moieties and proteasome 
mediated peptide ligation.
[5]
 A recent member to join this bandwagon of post translational 
modifications is „PROTEIN SPLICING‟.  
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Figure 2 The central dogma of biology. The central dogma of biology deals with the sequential 
transfer of information from DNA to RNA to proteins. It states that information cannot be transferred 
back from proteins to nucleic acids. 
 
1.1 Inteins and Protein Splicing 
 
In the early 1990‟s, it was discovered that the VMA1 gene from Saccharomyces cervevisiae 
encodes a 120 kDa translational product from which a 50 kDa endonuclease domain is 
excised out, producing the final mature product of 70 kDa.
[6]
 This deleted 50 kDa sequence 
present as an in-frame insert in the gene was later termed INTEIN (INTernal protEIN). 
Inteins are protein sequences present in the host protein sequence and must be removed in 
order to form a functional protein. In contrast to analogous introns, inteins are transcribed as 
well as translated together with their host protein.
[7]
 The two parts of the host protein 
separated by the disrupting intein sequence are called exteins (EXTernal protEIN).
[8]
 During 
post-translational processing this intein sequence is excised out by a process called „protein 
splicing‟ concomitantly joining its flanking extein sequences with a native peptide bond.[9] 
Two stable proteins, the mature protein and the intein are the products of the protein splicing 
process. 
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Since the discovery of the VMA1 intein, inteins have been identified in all three domains of 
life: eucaryotes, archaebacteria and eubacteria as well as in phages and viruses and range from 
134-608 amino acids. They have also been found in proteins with diverse functions, including 
metabolic enzymes, proteases, DNA and RNA polymerases, helicases, gyrases and vacuolar 
type ATPase.
[10]
 The intein regristry InBase at http:// www.neb.com/inteins.html has listed 
more than 450 inteins along with their sequences, conserved motifs, host organisms and host 
proteins.
[11]
 Intein names include a genus and species designation, abbreviated with three 
letters, and a host gene designation according to the currently accepted nomenclature. For 
example, the S.cerevisiae VMA1 intein is known as Sce VMA1. Most known genes encode 
only one intein and inteins found at the same insertion site in homologous proteins in different 
organisms are called intein alleles.
[12]
 In very rare cases, such as the ribonucleotide reductase 
gene of the oceanic N2-fixing cyanobacterium Trichodesmium erythraeumsome, four inteins 
are encoded.
[13]
 
Inteins are considered as parasitic selfish genetic elements as they contribute no known 
advantage to their host. However, due to their apparent negligible disruption of their host gene 
or the protein product formed, they are not weeded out. In addition, endonucleases integrated 
into some inteins results in transfer of the inteins into intein-less alleles. Endonucleases prefer 
inteins as integration sites because in these locations the functions encoded by the 
surrounding DNA would not be disrupted.
[14]
 Also, since inteins are inserted in highly 
conserved points in genes coding for essential proteins, their removal can be detrimental.
[15]
 
 
1.1.1 Intein Classification  
 
Inteins are classified into four groups, large (maxi), minimal (mini), trans-splicing and Ala 
inteins
[16]
: 
Large or maxi inteins (Figure 3) consist of two domains: a self-splicing domain and an 
endonuclease domain. They were the first to be discovered. The homing endonucleases are 
site-specific, double strand DNA endonucleases that promote intein spread between genomes 
in a recombination dependent process known as „homing‟. Usually, homing endonuclease are 
encoded by an open reading frame within an intein.
[17]
 The N- and C-terminal regions of the 
large inteins contain the elements necessary for splicing. The Sce VMA1 intein belongs to this 
class. 
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Figure 3 Schematic representation of a maxi-intein along with conserved intein motifs and 
numbering. Blocks A and B are present in the N-terminal splicing domain, while F and G are in the 
C-terminal splicing domain. The endonuclease domain contains the blocks C, D, E and H. The first 
amino acid residue upstream of the intein is numbered -1 with numbering continuing upstream. The 
intein is numbered sequentially beginning with the N-terminal amino acid residue. The first C-extein 
residue is the +1 position with numbering proceeding toward the C-terminus. 
 
Mini-inteins (Figure 4) have the typical N- and C-terminal splicing domains; however, the 
endonuclease domain is not present. The earliest mini-inteins were created by deleting the 
endonuclease domain at the gene level from the Sce VMA or the Mycobacterium tuberculosis 
RecA inteins.
[18]
 Splicing in the absence of this endonuclease domain demonstrated the 
sufficiency of the protein splicing domains for activity. Shortly thereafter, the naturally 
occurring mini-intein was reported in the Mycobacterium xenopi gyrA gene.
[19]
 The smallest 
known mini-intein Mth RIR1 intein is only 134 amino acids long and contains all the 
information necessary for splicing.
[20]
 
 
Figure 4 Schematic representation of a mini-intein. The mini inteins lack an endonuclease domain 
but the remaining conserved residues are the same as a maxi intein. The endonuclease region has been 
replaced by a short linker region.  
 
Trans-splicing inteins or split inteins (Figure 5) lack a covalent linkage between their N- and 
C-terminal splicing domains. Trans-splicing was demonstrated using artificially split inteins 
before a naturally split intein was discovered.
[21]
 The naturally split Synechocystis sp DnaE 
intein is characteristic of this class of inteins. 
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Figure 5 Schematic representation of a split intein. These inteins lack a covalent linkage between 
their N- and C-terminal splicing domains. 
 
Alanine inteins (Figure 6) contain a naturally occurring N-terminal alanine residue instead of 
the conserved cysteine or serine reported for the earlier inteins. The Methanococcus 
jannaschii KlbA intein belongs to this class of inteins. 
 
Figure 6 Schematic representation of an Ala intein. These inteins begin with an Ala instead of the 
conserved C, S or T. They belong to the Class II inteins and splicing proceeds via an alternative 
splicing mechanism where the first C-extein amino acid directly attacks the amide bond at the N-
terminal splice junction. 
 
1.1.2 Conserved Motifs 
 
Intein sequence analysis has revealed conserved motifs, blocks A, B, F, G, N2 and N4 which 
are found in all inteins. Groups of related amino acids populate these conserved motifs.
[22]
 
Blocks A and B are present at the intein N-terminus, blocks F and G are at the C-terminus and 
blocks N2 and N4 are close to the N-terminal.
[11-12, 22b, 23]
 Maxi inteins with an endonuclease 
domain have another four conserved motifs (blocks C, D, E, and H) (Figure 3).  
Known inteins share a low degree of sequence similarity with most inteins beginning with Ser 
or Cys and ending in His-Asn. However, several putative inteins are known to begin with Ala 
(see Alanine inteins; section 1.1.1), Gln and Pro or end in Asp and Gln.
[24]
 The first amino 
acid of the C-extein is an invariant Ser, Thr or Cys. Block B contains a highly conserved His 
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and a less conserved Thr residue. However, residues proximal to the intein-splicing junction 
at both the N- and C- terminal exteins were recently found to influence protein splicing.
[25]
 
Protein splicing has so far not been observed in multicellular organisms. However, the 
hedgehog autoprocessing domain in the hedgehog family of embryonic signaling protein from 
Drosophila melanogaster and the splicing domain of inteins have a common structural fold 
(the HINT module) which share two motifs (blocks A and B) and perform similar chemical 
reactions.
[26]
 The HINT (hedgehog intein) module is composed largely of β-strands and forms 
a horseshoe-shaped structure with two large β-strands forming the horseshoe core. The N- and 
C-terminal splice junction residues reside in the central cleft of this horseshoe-like structure in 
the form of antiparallel β-sheet. The splice junction residues are tightly associated with 
numerous hydrogen bonding contacts and hydrophobic packing interactions. 
 
1.1.3 Mechanism of Protein Splicing 
 
The widely accepted mechanism for protein splicing pathway is known to proceed via 4 intra-
molecular steps
[14, 27]
 outlined in Figure 7 
I. N      X acyl shift (X is either S if the first intein residue is Cys or O if the residue is Ser)  
Protein splicing is initiated by the side chain attack of the first intein residue on the preceding 
carbonyl (C=O) group, resulting in a shift of the N-extein to the side chain of the first intein 
residue and forming a thioester bond. 
II. Transesterification 
The hydroxyl or thiol group of the first C-extein residue (Ser, Thr, Cys) attacks the thioester 
linkage resulting in the transfer of the N-extein to the side chain of the +1 residue forming a 
branched thioester intermediate. 
III. Asparagine Cyclization 
Cyclization of the C-terminal Asn residue of the intein results in the removal of the intein due 
to the cleavage of the amide linkage yielding exteins linked by a thioester bond. 
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IV. S     N or O     N acyl rearrangement 
A spontaneous acyl shift results in a stable peptide bond being formed between the exteins.  
Most known inteins fall into the category of Class I inteins which carry out the standard 
protein splicing steps mentioned above. The importance of the splice junction residues 
mentioned in section 1.1.2 was clearly explained by the splicing mechanism outlined above. 
However, it did not account for the penultimate His and the block B Thr and His residues. It 
was later demonstrated by mutation and structural studies that the block B His assists in 
activating the N-terminal splice junction.
[27b, 28]
 The less conserved Thr was also shown to 
assist in N-terminal reactions. The penultimate His (His-Asn) activates the C-terminal splice 
junction for Asn cyclization. Mutating this residue in various inteins led to either no effect or 
total inhibition of the splicing reaction. 
In addition, an alternative splicing process is carried out by the alanine inteins (see section 
1.1.1) also known as the Class II inteins. In this case, the first residue of the C-extein (Cys) 
directly attacks the amide bond at the N-terminal splice junction leading to the formation of 
the branched intermediate thereby bypassing the first acyl shift initiation step.
[29]
 
In the Class III intein of the mycobacteriophage Bethlehem DnaB protein, a Cys residue 
present in the conserved block F attacks the peptide bond at the N-terminal splice junction 
forming a branched intermediate with a labile thioester linkage. In the next transesterification 
step, the N-extein is transferred to the +1 residue of the C-extein, a Thr, resulting in the 
branched intermediate as in Class I inteins.
[30]
  
Inteins with the conserved C-terminal Asn replaced by Asp or Gln have also been discovered 
as mentioned in section 1.1.2.
[31]
 These residues are capable of similar cyclization reactions as 
Asn, although other mechanisms have been proposed. 
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Figure 7 Protein splicing mechanism. The side chain sulfhydryl or hydroxyl of the intein N-terminal 
residue initiates an N-S or N-O acyl shift. This forms a (thio) ester linkage between the N-extein and 
the intein. The downstream nucleophile, side chain of Cys, Ser or Thr attacks the N-terminal (thio) 
ester in a trans (thio) esterification reaction to generate a branched intermediate. Cyclization of the 
intein C-terminal Asn coupled to peptide bond breakage releases the intein. The (thio) ester bond 
between the N-and C-exteins is converted to a native peptide bond by a spontaneous S-N or O-N acyl 
rearrangement. 
 
1.1.4 Side Reactions 
 
An excised intein and a ligated extein are the products expected after the completion of the 
above mentioned splicing process. However, products from side reactions are also obtained in 
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addition. N-terminal cleavage and C-terminal cleavage reactions only occur when inteins are 
inserted into foreign contexts or made to function under non-physiological conditions, for 
example, expressing splicing precursors in a heterologous host. These products arise from 
cleavage at either one or both splice junctions. Hydrolysis of the linear thioester intermediate 
or the branched intermediate prior to Asn cyclization results in cleavage at the N-terminal 
splice junction. On the other hand, cleavage at the C-terminal splice junction arises due to the 
Asn cyclization without the N-extein transesterification step. Mutating catalytic residues at 
one junction generally increases the cleavage reactions at the other junctions.
[32]
 For example, 
mutation of the Asn residue at the intein C-terminus abolishes steps 3 and 4 of the splicing 
reaction resulting in N-terminal cleavage but step 1 can still occur. Spontaneous hydrolysis of 
the linear thioester bond separates the N-extein from the intein/C-extein part. Replacing the 
conserved first N-terminal residue of the intein abolishes steps 1, 2 and 4 of the splicing 
reaction leading to C-terminal cleavage. In such a case, step 3 still occurs separating the C-
extein from the N-extein/intein portion. 
 
1.1.5 Effect of the Proximal Extein Amino Acids 
 
Inteins in their natural context have co-evolved with their extein sequences for maximum 
splicing efficiency. Therefore, placing them in heterologous insertion sites leads to a ~10-fold 
lower splicing efficiency and/or yields inactive precursor or cleavage byproducts.
[27b, 28a, b, 33]
 
Also, different inteins show different substrate specificity. Amino acids that are most similar 
to the native residue (for example amino acids of comparable size, shape and polarity) work 
best under these conditions. It has also been observed that splicing with inteins in a non-native 
context becomes temperature dependent suggesting that folding of the intein is impaired.
[18b, 
19, 34]
 All three nucleophiles involved in the protein splicing pathway are splice-junction 
residues; therefore, suboptimal proximal extein sequences may lead to destabilization of the 
active site and finally inhibit splicing. 
Data from the past few years have demonstrated the effect of the adjacent N-extein (N-1) and 
two C-extein residues (C+1, C+2) on splicing activity.
[3, 32a, 32c, 35]
 Amitai et al. recently 
reported that a bias also exists for the N-2, C+2 and C+3 extein sequences.
[25]
 They identified 
a number of N-1 residues that preferentially enhance or decrease the rate of N-terminal 
cleavage. The C+3 amino acid was shown to enhance N-terminal cleavage activity. It is 
therefore generally accepted that splicing is improved when 1-5 native extein sequences flank 
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the intein on either or both sides. Also, the further away the amino acid is from the intein the 
less likely it will have a significant impact on the splicing reaction. 
 
1.1.6 Effect of Divalent Cation 
 
The Zn
2+
 ion has been shown to affect splicing. It has been reported that splicing is inhibited 
when Zn
2+
 was added to the reaction mixture of the two intein halves for the Mtu RecA and 
the Ssp DnaE intein.
[36]
 Zn
2+
 was also shown to be present in the active site of the Sce VMA1 
intein. Although not involved in large structural perturbations, it was in contact with the 
penultimate His and the +1 Cys residues. However, till date it is still speculative whether the 
Zn
2+
 binds to and interferes with a folded intein. Zn
2+
 ions interference with the activity of an 
intein in vivo also remains to be determined. Cu
2+[37]
 and Cd
2+[36a]
 are also known inhibitors of 
protein splicing activity. It was therefore hypothesized that metal ion co-ordinations have 
negligible influence on protein structure. Mobility restriction of key residues from metal 
coordination is likely the key cause of metal inhibition of intein splicing.
[38]
 
 
1.2 Split Inteins and Protein Trans-Splicing 
 
Split inteins/Trans-splicing inteins (section 1.1.1) can be artificially engineered from 
contiguous inteins by dividing the intein into two parts and further reassembled to yield an 
active protein splicing element. This phenomenon was demonstrated both in vivo and in vitro 
in the 1900‟s by several independent groups.[18a, 21] These so called split inteins self-associate 
and catalyze protein splicing activity in trans termed „Protein trans-splicing (PTS)‟. 
PTS proceeds similarly as protein splicing; however, the first step involved is association of 
the intein fragments and their folding into an active conformation (Figure 8). A protein of 
interest (POI) is reconstituted from two fragments and the two polypeptide chains get linked 
by a native peptide bond. The intein fragments are excised making the linkage virtually 
traceless. 
Inteins can be split both within the splicing domain as well as within the endonuclease 
domain. Splicing was found to be more efficient using a split mini-intein with the split at the 
endonuclease insertion position. Recently, several other split positions have also been 
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identified.
[39]
 However, fusion proteins with artificially split inteins show reduced solubility 
and are only soluble if the complementary pairs are co-expressed or if fused to a solubility 
enhancing domain. Therefore, this often necessitates an undesirable denaturation/renaturation 
step prior to splicing. This suggests that artificially split inteins often have exposed 
hydrophobic domains which lead to protein aggregation due to misfolding in the absence of 
the complementary fragment. The tendency to aggregate may contribute to reduced splicing 
efficiency.
[21a, b, 40]
 The Ssp DnaB
[41]
 and the Mxe GyrA
[42]
 artificially split inteins have been 
reported to retain solubility and splicing activity under native conditions using purified 
proteins. 
 
Figure 8 Protein trans-splicing mechanism. Both artificially and naturally split inteins undergo 
proteins trans-splicing via the mechanism outlined above. Intein association is the first step in PTS 
and the following steps are the same as for contiguous inteins. For a comparison with the protein 
splicing mechanism of contiguous inteins see Figure 7. 
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Naturally occurring split inteins lack an endonuclease domain and the split site corresponds to 
the location of this missing domain. This region often coincides with a loop region within the 
intein structure.
[43]
 They are believed to be descendants of a continuous mini-intein which 
later lost its sequence continuity due to one or more genomic rearrangements. Naturally split 
inteins are generally believed to exhibit better solubility due to higher affinity among intein 
fragments and because they are naturally expressed as separate fragments compared with 
artificially split inteins.
[44]
 One of the best characterized naturally split inteins (DnaE intein) is 
found in the dnaE gene of a large group of cyanobacteria. 
Split intein engineering of naturally split inteins have recently revealed that new split inteins 
can be created by introducing split sites at locations differing from the canonical split site of 
the intein. These split sites must however correspond to surface loops.
[45]
 Similarly, new split 
sites have also been engineered for artificially split inteins. The Ssp DnaB intein split at four 
new positions was found to show protein splicing activity.
[39]
 PTS was carried out with an N-
intein fragment that is only 11 amino acids long.
[46]
 Split Ssp GyrB intein with a C-intein 
fragment of 6 aa has also been reported.
[47]
 
 
1.2.1 The DnaE Intein 
 
Cyanobacteria are a large and diverse group of bacteria and it was recently reported that the 
split intein of the dnaE gene is quite common in several groups of these cyanobacteria.
[48]
 The 
catalytic α subunit of the DNA polymerase III (DnaE protein) was found to be encoded by 
two genes in several cyanobacteria- Synechocystis species PCC 6803 (Ssp), Synechococcus 
species PCC 7002, Nostoc species PCC 7120, Nostoc punctiforme (Npu), 
Thermosynechococcus elongates (Tel) and Trichodesmium erythaeum (Ter). The dnaE gene 
coding sequences are split in the exactly same extremely conserved point into two genes. The 
N-terminal part of the dnaE gene is followed by a N-terminal part of the split intein. 
Similarly, the C-terminal half of the dnaE gene is preceded by a C-terminal half of the split 
intein. The DnaE split intein amino acid sequence is conserved along their entire sequence 
except for the 3‟ end of the N-terminal half which differ from each other in sequence and in 
length. The length of the DnaE
N
 part is between 101 and 123 aa and the DnaE
C
 is usually 35-
36 aa is length. All the DnaE inteins studied so far have the six conserved sequence motifs 
that define the intein protein splicing fold and active site and none of them has an 
endonuclease domain. dnaE genes present in other cyanobacteria like Prochlorococcus 
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marinus are contiguous with no inteins and are flanked by the same genes. However, split 
dnaE genes are flanked by different genes. DnaE split intein amino acid sequences are more 
similar to each other than other inteins. Split intein genes are unlikely to be transferred by 
homing as both need to be copied at the same time and also because of the lack of the 
endonuclease domain. 
Although the Ssp DnaE from Synechocystis species PCC 6803 (Ssp) is one of the better 
studied and broadly used split inteins, the present work employs the Npu DnaE intein from 
Nostoc punctiforme. In order to appreciate the superior properties of this intein and 
understand the reasons for its use in this work, a comparison with the Ssp DnaE intein is 
however necessary. 
 
1.2.2 The Ssp DnaE and the Npu DnaE Split Inteins 
 
The Ssp DnaE and the Npu DnaE inteins are members of a family of naturally split DnaE 
inteins all of which use the canonical “CFN” tripeptide splice junction but whose splicing 
activities differ from each other.
[3, 49]
 
The DnaE protein of Synechocystis species PCC 6803 is coded by a split gene interrupted by a 
split intein. The N- and C-terminal halves of the catalytic subunit α of DNA pol III are 
encoded by two separate genes located ~750 kb apart in the genome and on opposite DNA 
strands.
[43a]
 The dnaE-n product consists of a N-extein followed by a 123 aa intein N-terminal 
sequence (Int
N
) whereas the dnaE-c product consists of a 36 aa intein C-terminal sequence 
(Int
C
) followed by the C-extein sequence. Co-expression of the intein halves in E.coli 
produced an intact DNA pol III.
[43a]
 
The intein halves have been shown to perform spontaneous trans-splicing both in vitro and in 
vivo in a foreign context.
[49b, 50]
 It is known from literature that trans-splicing with this intein 
also generates cleavage products, together with stable complexes of noncovalently, tightly 
interacting intein intermediates.
[51]
 Kinetic analysis suggests extreme rapidity of association 
and a slow dissociation. Protein trans-splicing is extremely rapid (6.6 ± 1.3 x 10
-5
 s
-1
) and 
occurs at a low nanomolar affinity.
[44, 51-52]
 The crystal structure obtained with artificially 
joined split intein halves revealed a high structural similarity to the characteristic compact 
intein fold and its active site.
[43d]
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The Npu DnaE intein present in the α subunit of the DNA pol III gene of Nostoc punctiforme 
came into the limelight because of a recent discovery that this DnaE intein besides having the 
obvious advantages of naturally split inteins, is more robust in protein trans-splicing than the 
Ssp DnaE intein.
[3, 49b]
 
The naturally split Npu DnaE intein is homologous to the Ssp DnaE with a sequence identity 
of 67 % (68/102) for the N-terminal intein and 53 % (19/36) for the C-terminal intein half. 
The C-terminal fragment of the Ssp DnaE contains 21 aa lacking in the Npu DnaE intein, 
which is not involved in the intein structural fold
[43d]
 and is dispensable for the splicing 
activity. Furthermore, all known conserved amino acids essential for catalytic activity are 
identical in both cases. Therefore, one can only speculate upon the origins of the unique 
properties of this intein. 
The Npu DnaE can perform spontaneous trans-splicing in vivo in a foreign context.
[49b]
 In 
comparison to the Ssp DnaE amount of unprocessed precursor is 20 fold less with a splice 
product yield more than 10-fold higher in comparison to the Ssp. It is known to display by far 
the highest rate constant in the protein trans-splicing reaction (with a t1/2 of about 1 min at 
37 °C using purified proteins) while many split inteins including the Ssp DnaE intein exhibit 
reduced yields and increased formation of hydrolysis side products at this temperature.
[49b]
 
Also, in contrast to the Ssp DnaE
N
, the Npu DnaE
N
 can accommodate many substitutions at 
the second residue of the C-terminal extein (Phe+2) with no or modest reduction in the trans-
splicing activity thereby increasing the applications of trans-splicing as it has often been 
limited by the inevitable insertion of the native extein sequence at the ligation junction.
[3]
 The 
two split inteins were also found to have cross-splicing activity
[3]
 but the rate of the reaction 
was compromised suggesting that only a native combination of the Npu intein fragments was 
capable of performing the superior trans-splicing activity reported.  
Thus, it is evident that the Npu DnaE intein holds great promise and has potential for 
becoming an invaluable tool in various areas of biotechnology with drastically shortened 
reaction times and high yields being the major selling points. Its robustness under high urea 
conditions and ability to splice efficiently even at lower temperatures will see its applications 
where poorly soluble or temperature sensitive proteins are required. Moreover, an engineered 
split Npu DnaE intein with a shortened C-terminal fragment
[43b]
 will allow labeling of proteins 
via protein semi-synthesis. 
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1.3 The PCP domain 
 
Non-ribosomal peptide synthetases (NRPSs) are large modular enzymes which are 
responsible for the synthesis of a variety of microbial bioactive peptides.
[53]
 An NRPS 
comprises of a set of distinct modules, with each module consisting of defined domains.
[54]
 
These modules each recognize and incorporate one specific amino acid into the peptide 
product. Each amino acid of the peptide product undergoes adenylation, thioester and peptide 
bond formation as well as substrate modifications catalyzed by these domains. An amino acid 
is activated by the adenylation domain (A) to form the aminoacyl adenylate.
[55]
 The peptidyl 
carrier protein (PCP) is the thioester domain of these modules.
[56]
 This domain is subjected to 
phosphopantetheinylation at a Ser residue within a conserved sequence motif of the PCP 
domain shown in Figure 9 which converts the apo-PCP (inactive) to the holo (active) form. 
This reaction, catalyzed by phosphopantetheine transferases (PPTases) occurs by tethering the 
phosphopantetheinyl moiety of cosubstrate coenzyme A (CoA) in phosphodiester linkage to 
the hydroxymethyl side chain of the conserved serine residue in the PCP domain.
[57]
 The PCP 
domain, under native conditions, tethers the activated amino acylated product to the 
csyteamine thiol group of 4‟-PP. The activated amino acid fixed to the PCP can undergo 
further optional modifications.
[56, 58]
 The downstream condensation domain (C) then catalyzes 
peptide bond formation between the amino acids bound to the 4‟-PP cofactors of the PCP 
domains in two adjacent modules. This results in a peptide product tethered to the second PCP 
domain and release of the free –SH group of the first 4‟-PP.[59] In this way the reaction is 
continued until all amino acids are incorporated into the peptide chain which is then released 
from the last module by hydrolysis or cyclisation.
[60]
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Figure 9 Ribbon model of the solution structure of the PCP domain. Sequence of the PCP 
domainof the TycA gene from B.brevis. The 4‟-PP binding site is underlined with the CoA attachment 
site (Ser) marked with a blue arrow. PDB ID: 1DNY 
 
1.4 Fluorescence cross-correlation spectroscopy 
 
For understanding the function and regulation of a protein it is crucial to understand the 
repertoire of interactions it undergoes with other molecules. Several biochemical and 
biophysical techniques have been developed for investigating such interactions and each of 
these approaches have their own strengths and weaknesses especially with regard to the 
sensitivity and specificity of the method.
[61]
 Biochemical approaches such as co-
immunoprecipitation (CoIP) and Yeast two-hybrid (Y2H) have been extensively applied for 
studying protein-protein interactions between various proteins.
[61b, 62]
 These techniques have 
been further extended in real time in living cells with the aid of various forms of fluorescence 
microscopy. However, pairs of interacting proteins are too small to be resolved by 
conventional fluorescence microscopy. Fluorescence resonance energy transfer (FRET)
[63]
 
and fluorescence cross correlation spectroscopy (FCCS)
[64]
 have overcome this barrier and it 
is therefore now possible to investigate protein-protein interactions using fluorescence 
microscopy. 
FCCS, an extension of the popular fluorescence correlation spectroscopy (FCS) technique
[65]
 
is a method that measures the temporal fluctuations emanating from two differently labeled 
molecules diffusing through a small sample volume.
[64, 66]
 The basic concept of FCS is to 
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make the number of observed molecules low enough so that each of them contributes 
substantially to the measured signal. The parameter of primary interest in contrast to other 
fluorescence techniques is not the intensity of the fluorophore itself, but rather the 
spontaneous intensity fluctuations caused by the minute deviations of the small system from 
thermal equilibrium. The fluctuations can be quantified in their strength and duration by 
temporally autocorrelating (A mathematical representation of the degree of similarity between 
a given time series and a lagged version of itself over successive time interval) the recorded 
intensity signal.
[67]
 
In dual colour FCCS interacting molecules can be tagged with spectrally different 
fluorophores and their interaction studied by following intensity fluctuations of both 
molecules (Figure 10). By separately labeling the reactants with differently emitting 
fluorophores, the probes can be simultaneously excited with two different laser lines and 
detected in separate channels. The signals from both channels are cross-correlated in time and 
the doubly labeled products can be easily distinguished from the singly labeled reactants, 
independent of their mass. This was earlier not feasible with FCS as the sensitivity of this 
technique to detect binding of two or more components depends on the relative change in 
mass upon binding which is not pronounced in a multi-component system where the mass of 
the product should differ from the reactants by at least a factor of 4.
[68]
  
The basic characteristics of an FCS and FCCS setups are the choice of laser lines, dichroics 
and filters. FCCS with dual laser excitation involves the use of two spectrally distinct 
fluorophores each of them excited by one of the lasers.
[64]
 This offers the highest signal to 
noise ratio since different fluorophores can be excited with lasers having excitation 
wavelengths that match the fluorophores‟ absorption maxima. Fluorophores can also be 
chosen to have widely separated emission wavelength to minimize cross-talk. This requires 
matching the two laser beams to the same focal spot to maximize the two excitation volumes 
and detection volumes making it experimentally challenging.
[69]
 Single wavelength FCCS 
(SW-FCCS) overcame this limitation as it uses a single laser line for the excitation of two 
fluorophores with similar excitation but different emission spectra due to distinct Stokes 
shifts.
[70]
 This had the advantage that it eliminated the problems of chromatic aberrations 
which caused displacement shifts in the observation volume in the previous case and the 
requirement for focal volume overlap. Resolution could be improved by increasing the S/N 
ratio through maximizing counts/min and minimizing detector cross-talk. This is influenced 
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by several factors, importantly fluorophore brightness as there is currently a lack of bright 
fluorophores with a wide range of Stokes shifts excited by a single laser line. 
 
Figure 10 Schematic representation of the FCCS phenomenon. A green fluorescently labeled 
molecule on passing through the observation volume is detected as a fluctuation in the green channel 
and an auto-correlation curve is obtained for the molecule. Similarly, a red fluorescently labeled 
molecule will result in a fluctuation being observed in the red channel. An interaction between these 
two molecules will result in simultaneous fluctuations being observed in both the red and green 
channels and the cross-correlation curve thus obtained provides characteristic information about the 
interacting molecules. 
 
FCCS applications require probes with high quantum yields and long-term photostability. It is 
also advantageous for dyes to have narrow emission spectra for minimal cross talk as red-
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shifted dyes usually tend to have broader emission spectra. Organic dyes, quantum dots 
(QD‟s) and fluorescent proteins have been used for various FCS applications.[71] Quantum 
dots in general are superior to organic fluorophores and genetically encoded fluorescent 
proteins in various aspects such as long-term photostability, high quantum yield, multiple 
labeling with several colors and single wavelength excitation for all colors. Quantum dots are 
semiconductor nanocrystals that are coated with a polymer shell or other ligands that allow 
the materials to be conjugated to biological molecules.
[72]
 They have the unique property of 
size dependent emission wavelengths.
[73]
 However, quantum dots have limitations which 
occur due to their blinking characteristics (random switching between bright and dark states), 
aggregation tendency and large size which affects the mobility of the target molecule.
[74]
 
Nevertheless, they hold great promise as fluorescent probes due to their intense brightness, 
low photobleaching rate and tunable emission wavelengths with broad absorption spectra. 
 
1.5 Application of Inteins in Biotechnology 
 
Since their discovery in the nineties, much has been learned about inteins. Crystal structures, 
kinetics and mutagenesis studies have further added to the understanding of inteins and the 
splicing reaction. The potential of these inteins as powerful tools for protein engineering has 
been recognized in the last decade and a number of intein-based technologies have been 
developed. 
Intein mediated protein ligation has been used for ligating peptides and proteins.
[75]
 Intein 
applications have included segmental labeling of proteins for NMR analysis,
[43b, 76]
 cyclization 
of proteins,
[50a]
 controlled expression of toxic proteins,
[77]
 quantum dot conjugation to 
proteins
[78]
 and incorporation of unnatural amino acids.
[79]
 Furthermore, assembly of modular 
proteins from fragments has been accomplished by PTS resulting in a biologically active full-
length protein. This has allowed monitoring of in vivo protein-protein interactions
[80]
 and 
spatio-temproal expression of proteins using reporter genes like enhanced green fluorescent 
protein (EGFP)
[81]
 and luciferase
[82]
 for the production of transgenic plants by reconstitution 
of herbicide resistance proteins.
[83]
 PTS has also been useful for translocating proteins into 
cellular organelles,
[17a, 84]
 for gene therapy
[85]
 and recently for reconstitution of a membrane 
protein.
[86]
 A few of the important applications of inteins are discussed below. 
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I. Intein mediated protein ligation: 
(IPL) or expressed protein ligation (EPL) is well established in molecular biology.
[28b, 87]
 It is 
an in vitro technique that ligates polypeptides having an intein generated C-terminal α-
thioester with polypeptides starting with Cys and a peptide bond is formed after the ligation 
(Figure 11). Various molecules can be ligated with this methodology, however only if it has a 
Cys with a free amino group. PNA
[88]
 or DNA
[89]
 tags have been linked to proteins using EPL. 
 
Figure 11 Expressed protein ligation. Trans-thioesterification of the protein α-thioester by the N-
terminal Cys polypeptide is followed by an S to N acyl shift to generate a new peptide bond linking 
the two polypeptides. -thioesters can be obtained recombinantly, using  engineered inteins, or by 
chemical synthesis. N-terminal Cys polypeptides can also be produced recombinantly or made using 
standard SPPS. 
 
II. Protein semi-synthesis: 
Split inteins have been used as versatile tools for protein semi-synthesis (generating a 
polypeptide from an expressed recombinant protein and a segment obtained by organic 
peptide synthesis). Short Int
C
 or Int
N
 fragments can be chemically synthesized with a small C-
extein or N-extein sequence by solid phase peptide synthesis and the remaining protein is 
fused to the complementary intein fragment by recombinant gene expression. Split inteins 
with extremely short N- and C-terminal halves are of particular interest in protein labeling 
because they can provide a facile means for the site-specific incorporation of unnatural amino 
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acids, fluorescent labels or other biophysical probes into a protein in combination with 
chemical synthesis (Figure 12). PTS between a target protein fused to the remainder of the 
split intein and the engineered peptide results in a labeled POI.
[46, 90]
 Giriat and Muir reported 
the semisynthesis of proteins in living cells.
[91]
 
 
Figure 12 Protein semi-synthesis. The scheme depicts semisynthesis of N-terminally modified 
proteins using protein splicing in trans. In a similar manner, proteins can be modified at their C-
terminus by chemically synthesizing a short Int
C
-fragment and reacting with the recombinantly 
produced complementary half. 
 
Regioselective fluorescent labeling of a protein of interest containing more than one cysteine 
can also be achieved by combining PTS with cysteine bioconjugation.
[42, 86, 92]
 Split inteins 
lacking a cysteine at the splice junction and also free of cysteines in the remaining sequence 
are well suited for this purpose. The Int
C 
fragments of the artificially split Ssp DnaB
[92a]
 and 
Mxe GyrA
[42]
 inteins are cysteine free and serine and threonine occupy the +1 position, 
respectively. A short peptide sequence with a single cysteine, termed the Cys tag was 
expressed in fusion with these intein fragments and labeled. Ligation by PTS to proteins with 
multiple cysteines resulted in a chemically modified protein of interest (Figure 13). An 
internal cysteine residue within a POI is addressed by splitting the POI itself and 
reconstituting via PTS.
[86]
 
The end result of both IPL and PTS is the formation of a native peptide bond and both 
techniques have been used in numerous types of modifications.
[27b, 28a, b, 88-89, 91, 93]
 However, 
both differ from each other in the following points: PTS is driven by strong attractive forces 
whereas EPL is driven by mass action. The intein generated α-thioester allows ligation of 
numerous types of molecules besides polypeptides whereas PTS is limited by the substrate 
preferences of the split intein. Nevertheless, in favor of PTS, the intein directly forms a 
peptide bond between the two exteins and a chemical reaction is not required. This implies 
that synthesis of a thioester or any other functional group is not a prerequisite and high 
concentration of thiols is unnecessary. Furthermore, the high affinity and specificity between 
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the split intein fragments permits the reaction to be performed at low micromolar to 
nanomolar concentrations and in the presence of other proteins, for example, in a cell lysate. 
 
Figure 13 Combining PTS with cysteine bioconjugation. A short peptide tag with a single cysteine 
is chemically modified with a labeling reagent. In a second step, ligation by PTS  results in a modified 
protein. This approach circumvents the problem of regioselective labeling of proteins containing more 
than one essential cysteine. The split intein fragment fused to the Cys-tag should be free of any 
catalytic cysteines. 
 
III. Segmental isotopic labeling 
Conventional NMR techniques are generally limited to low molecular weight proteins of upto 
30 kDa. Segmental isotope labeling of N- and C-terminal protein segments has been 
established both in vitro and in vivo using the PI-PfuI intein and PTS which has allowed for 
the labeling of larger proteins.
[40, 76, 94]
 Multi-fragment ligation was also successfully 
performed with orthogonal inteins for labeling at an internal segment of a protein with a 
heavy atom in NMR spectroscopy.
[93, 95]
 
 
IV. Protein-purification 
Purification of a variety of proteins has been facilitated by inteins.
[96]
 The principle involves 
an exchange of the exteins of an engineered intein between the purification tag and the target 
protein (Figure 14). Splice junction residues are mutated to abolish splicing. After 
immobilization of the POI either the N-terminal cleavage reaction is induced by DTT or a C-
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terminal cleavage by a pH or temperature shift resulting in release of the POI. The intein 
mediated purification with affinity chitin-binding tag (IMPACT) is commercially available. 
 
Figure 14 Intein mediated protein purification. A mutated intein variant is used for the purification 
of a protein fused to its N-terminus. A chitin binding domain (CBD) is fused to the C-terminus of the 
intein and purification is performed by utilizing a chitin column. The intein is mutated at the C-
terminus Asparagine so that cleavage only occurs at the N-terminus which results in the release of the 
target protein from the column. 
 
V. Conditional Protein Splicing 
Inteins can be used as in vivo molecular switches by conditional protein splicing. The 
engineered split fragments of Sce VMA1 intein were each fused to either a FKBP or FRB 
domain. The FKBP-FRB dimerize in response to rapamycin, triggering trans-splicing.
[97]
 
Similarly, different receptors were inserted into the Mtu RecA intein and splicing was 
activated in response to the respective ligands.
[98]
 Gene function in yeast and drosophila could 
be spatially and temporally controlled by inserting temperature sensitive splice mutants into 
transcription regulators.
[99]
 
 
VI. Cyclic peptide synthesis 
Split intein mediated circular ligation of peptides and proteins (SICLOPPS) has been 
demonstrated in vivo using the Ssp DnaE intein. The desired POI is inserted between a 
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circularly permuted split intein and PTS will result in the N- and C-termini of the target 
protein being joined together by a peptide bond. The order of the intein fragments was 
reversed in the precursor i.e. Int
C
-POI-Int
N
 and splicing resulted in a fully functional circular 
protein (Figure 15).
[50a, 100]
  
 
Figure 15 Schematic representation of intein mediated peptide/protein cyclization. The target 
polypeptide is flanked at its N- and C- termini by the Int
C
 and Int
N
 fragments, respectively. PTS ligates 
the N and C termini by a peptide bond generating a circularized peptide or protein. 
 
Thus, it is well documented in literature that modification of inteins both in vitro and in vivo 
is of biotechnological significance. Protein trans-splicing promises to provide further 
opportunities in the rapidly growing field of molecular and structural biology.  
 
 
1.6 Cell Surface Protein Labeling Strategies 
 
Visualization of proteins in living systems in real time have been key to understanding the 
spatiotemporal distribution, trafficking, binding interactions, stability, fate and function of 
either an individual or multiple proteins. Genetically encoded fluorescent proteins have been 
the dominant rulers in cellular imaging due to their remarkable stability and capacity to label 
proteins with absolute specificity. GFP and its variants have indeed revolutionized the ability 
to visualize and monitor proteins in vivo.
[101] However, this system also suffers from potential 
disadvantages. First, these proteins are large enough to interfere with the localization, 
structure or activity of the protein to which they are fused. The large size also greatly restricts 
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use for stie-specific labeling within a protein. Secondly, the barrel like structure isolates the 
chromophore from the cellular environment making fluorescent proteins poor probes for 
intracellular changes in pH or ion concentrations.
[102]
 There is only a finite potential for 
modifying the spectral and biochemical properties of fluorescent proteins.
[103]
 Fluorescent 
proteins are not very bright or photostable thereby making them unsuitable for single 
molecule microscopy. Precise control of the labeling ratio for multicolor FRET measurements 
is cumbersome with fluorescent proteins. These disadvantages have led to the development of 
alternate chemical labeling approaches. 
Site-specific labeling of proteins in vivo 
Site-specific labeling techniques in combination with fluorescence microscopy have been 
widely used to detect proteins in living cells. Labeling methods developed so far, rely on 
protein-ligand interaction, peptide-peptide interaction, peptide fluorophore interaction, metal 
chelation and enzymatic reactions.
[2, 104]
 Specificity in labeling integral membrane proteins 
can only occur if the protein of interest harbors a unique reactivity that distinguishes it from 
other biomolecules present on the cell surface. However, only in very few cases the intrinsic 
properties of a protein can provide such a unique functionality and therefore in majority of the 
cases, molecular tricks need to be employed. Several post-translational labeling methods are 
currently known which use a genetically encodable tag and synthetic probes which are 
specific for those tags. A good labeling strategy should possess high specificity for the target 
protein, does not interfere with the biochemical functions or cellular localization of the 
labeled protein and minimally perturbs the normal cellular processes. Criteria‟s such as cell 
permeability, non-toxicity, specific reactivity and good fluorescent properties should be 
carefully considered during the design and tailoring of small molecule probes.  
Some of the popular techniques currently utilized for site specific labeling of cell surface 
proteins have been discussed below. 
 
1.6.1 Non-covalent Methods 
 
I. Biarsenical Dyes 
This method developed by Tsien et al. exploits the well-known specificity of organoarsenicals 
with pairs of thiols (Figure 16).
[105]
 F1AsH, a cell permeable fluorescein derivative or 
ReAsH, a resorufin derivative was used to label a short peptide sequence CCXXCC (X= non-
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Cys) fused to a protein of interest. F1AsH contains two As (III) substituents conjugated to 
ethanedithiol (EDT). F1AsH bound to EDT is virtually non-fluorescent but upon binding to 
the CCXXCC motif, a marked increase in fluorescence occurs.
[106]
 
Used for studying the role of conformational changes in GPCR-mediated cell signaling
[107]
 
and activation.
[108]
  
 
Figure 16 Site-specific labeling of tetracysteine motif by F1AsH. A short peptide sequence 
CCXXCC (X is a non-cysteine amino acid) was genetically fused to the protein of interest which was 
subsequently recognized and labeled by F1AsH, a cell permeable fluorescein derivative. POI = Protein 
of interest. 
 
II. Labeling using DHFR fusion 
This non-covalent technique developed by Cornish et al. uses the well-described  interaction 
between methotrexate (Mtx) and the enzyme dihydrofolate reductase (DHFR) to label DHFR 
fusion proteins with fluorescent derivatives of Mtx.
[109]
 Mtx is a small molecule which binds 
with subnanomolar affinity to the monomeric protein, DHFR. An improved system using the 
bacterial DHFR and trimethoprim (TMP) has been recently described.
[109b]
  
E.coli dihydrofolate reductase (eDHFR) at the plasma membrane has been labeled by ligand 
TMP by fusing the N-terminus of eDHFR to the myristoylation/palmitoylation sequence 
MGCKISKGKD.
[109b]
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III. Reversible labeling with NTA probes 
Vogel et al. reported a site-selective and reversible method for labeling membrane proteins 
containing a polyhistidine sequence which was based on the known interaction between 
polyhistidine sequences and the Ni
2+
-NTA moiety.
[110]
  
Structure and plasma membrane distribution of the 5-hydroxytryptamine serotonin receptor 
(5HT3R) was studied by this approach in HEK 293 cells.
[110]
 
 
IV. Non-covalent labeling with FKBP12 
Nolan et al. devised a technique that made use of the tight interaction between a specific 
mutant of FK506-binding protein 12 (FKBP12) and the synthetic ligand SLF‟ that was 
derivatized with fluorescein. SLF‟ has sub-nanomolar affinity and an extremely high 
selectivity for FKBP12 and lacks the immunosuppressive effects of FK506 (original FKBP12 
ligand).
[111]
 
This approach was used to label a variety of proteins including caveolin, rac and rho in HeLa 
cells although only two types of fluorophores (TMR and fluorescein) were suitable for 
effective labeling.
[111-112]
 
 
V. Oligo-Asp/Zn
2+
complex labeling 
Hamachi et al. devised an elegant technique for labeling cell surface proteins based on metal-
ligand interaction. A short oligo- aspartate tag was fused to the protein of interest based on the 
fact that several carboxylate groups will react favorably with a cationic metal complex. 
Binuclear Zn(II)-DpaTyr fluorescein or cyanine derivatives were used as the metal 
complex.
[113]
 
CHO cells expressing the muscarinic acetylcholine receptor (mAChR) was successfully 
labeled with FITC using this technique without affecting its signaling activity.
[113]
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1.6.2 Covalent Methods 
 
I. Labeling using hAGT fusion 
Keppler et al. developed a strategy whereby specific covalent labeling was achieved using 
human O
6
-alkylguanine-DNA alkyltransferase (hAGT) (Figure 17). Function of hAGT in the 
cellular environment involves the repair of alkylated DNA where it irreversibly transfers the 
alkyl group from O
6
-alkylguanine DNA to one of its reactive cysteines and following this 
transfer the AGT is typically degraded. However, O
6
-benzylguanine (BG) and BG-derivatives 
substituted at the 4-position of the benzyl ring can also act as substrates. BG-derivatives 
containing biotin and fluorescein were successfully used for labeling hAGT fusion proteins 
[(G160W) mutant of hAGT which possess higher activity with BG] expressed in live cells. 
SNAP-tag- Efforts to decrease non-specific binding of BG derivatives to endogenous AGT 
lead to the identification of an inhibitor against wt AGT together with the generation of a 
mutant 
M
AGT which is refractory to this inhibitor. This SNAP-tag has reduced affinity for 
alkylated DNA and exhibits a 50-fold faster labeling kinetics.
[114]
 It was fused to the GPCR 
NK1 with an exoplasmic N-terminus.
[115]
 
Recently, this technique was used to specifically label cell-surface G-protein coupled 
receptors (GPCR‟S).[116] 
 
Figure 17 hAGT mediated protein labeling. Covalent labeling of a protein of interest fused to hAGT 
using O
6
-benzylguanine derivatives. The native activity of hAGT is to repair alkylated DNA by 
transferring the alkyl group from O
6
-alkylguanine DNA to an active site Cys residue of the hAGT 
enzyme. Here, the hAGT catalyzes the transfer of small molecule probes from O
6
-benzylguanine 
conjugates to the active site Cys. POI = Protein of interest, Red star = probe  
 
II. Halo-Tag mediated labeling 
Halo Tag protein is a ~33 kDa monomeric engineered haloalkane dehalogenase from 
Rhodococcus rhodochrous devised by researchers at Promega that cleaves carbon-halogen 
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bonds in aliphatic halogenated compounds. Nucleophilic attack by the haloalkane to Asp106 
in the enzyme results in the formation of an ester bond between the ligand and protein 
followed by ester hydrolysis to yield alcohol as the final product (Figure 18). A His272Phe 
mutant of the enzyme, which prevents ester hydrolysis, fused to the protein of interest would 
allow the covalent attachment of alkyl halide conjugated chemical probes to the Halo-Tag for 
protein labeling by forming a stable  bond with the substrate haloalkane.
[117]
 
Organic fluorophores like TMR and fluorescein as well as inorganic quantum dots have been 
attached to the extracellular domain of platelet derived growth factor receptors for long-term 
imaging.
[118]
 
 
Figure 18 Halo tag mediated protein labeling. Haloalkane dehalogenases under native conditions 
hydrolyze alkyl halides. In protein labeling reactions, chemical probes linked to an alkyl halide can be 
covalently conjugated to an active site Asp residue in the Halo tag. POI = Protein of interest, Red 
star = probe 
 
III. Labeling by enzymatic posttranslational modification 
Cutinase: This enzyme is a ~22 kDa globular, fungal serine esterase which under native 
conditions hydrolyzes cutin and is known to also hydrolyze fatty acid esters and triacayl 
glycerol.
[119]
 Fusion proteins can be targeted using probes based on the p-nitrophenyl 
phosphonate (pNPP) scaffold which is a suicide inhibitor for cutinase and forms a covalent 
adduct with the enzyme by conjugation with a specific Ser residue in the enzyme active site 
(Figure 19).
[120]
 In protein labeling catalyzed by cutinase, pNPP-SH derivatized with 
maleimide-functionalized fluorophores are transferred onto the cutinase fused to the target 
protein. 
Cell surface protein integrin LFA-1 expressed on the surface of BAF cells has been labeled 
with quantum dots or Alexa Fluor 488 to study the dynamic redistribution of the receptor.
[121]
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Figure 19 Cutinase catalyzed protein labeling. Native activity of cutinase is to hydrolyze the 
polyester linkages in cutin. For labeling proteins, small molecule probes are transferred from their 
phosphonate derivatives to a specific Ser residue in the cutinase tag. POI = Protein of interest, Red 
star = probe 
 
Biotin Ligase (BirA): In nature, BirA accepts only biotin and its derivatives as substrates for 
covalently attaching a biotin to a specific Lys side chain of the biotin carboxyl carrier protein 
(BCCP) in the multi-enzyme complex of Acetyl carboxylase A with an amide linkage. A two-
step labeling strategy was established by the group of Ting et al. where they demonstrated the 
acceptance of a ketone isostere of biotin by an E.coli BirA and transfer to the lysine side chain 
within a 15 amino acid acceptor peptide (AP) sequence (Figure 20). Incorporation of the 
ketone into the AP is followed by bio-orthogonal ligation with hydrazide or hydroxylamine 
bearing probes.
[104a]
 
Epidermal growth factor receptor (EGFR) expressed on the surface of HeLa cells was labeled 
by this procedure.
[104a]
 
 
Figure 20 General method for labeling acceptor peptide (AP)-tagged protein of interest using 
biotin ligase. Biotin ligase catalyzes the ligation of ketone to the AP. A subsequent bio-orthogonal 
ligation between ketone and hydrazide (or hydroxylamine) introduces the probe. POI = Protein of 
interest, Red star = probe 
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Lipoic acid ligase mediated labeling: Similar to the above mentioned biotin ligase strategy, 
a two-step labeling can be carried out by using lipoic acid ligase (LplA) which uses an alkyl 
azide as substrate instead of the native lipoic acid.
[122]
 An LplA acceptor peptide (LAP) was 
identified that could be appended to the target protein and the LplA ligates the alkyl azide to 
the ε-NH2 of the lysine side chain in the LAP sequence (Figure 21). This is followed by its 
derivatisation with a cyclo-octyne conjugate modified with dyes, QD‟s or biotin (Huisgen 
cycloaddition). 
Labeling of LAP-low density lipoprotein receptor (LDLR) fusion protein expressed on the 
cell surface was carried out which did not impair protein activity or trafficking. 
 
Figure 21 Scheme for lipoic acid catalyzed fluorescent tagging. Lipoic acid ligase ligates an alkyl 
azide to a lysine side chain within a peptide recognition sequence. The azide is selectively 
functionalized with a cyclo-octyne conjugate to a probe of interest to give a triazole adduct. POI = 
Protein of interest, Red star = probe 
 
Transglutaminase (TGase): TGases catalyze amide bond formation in multicellular 
organisms between glutamine and lysine side chains and are active during apoptosis, wound 
healing and migration events.
[123]
 Acyl transfer from the γ-carboxamide group of a Gln 
residue in one protein to the ε-amino group of a Lys residue in another protein establishes an 
isopeptide bond between the proteins (Figure 22). The TGase from guinea pig liver 
(gpTgase) exhibits high specificity for Gln containing proteins which act as acyl donors and 
low specificity for the Lys containing proteins which end up as acyl acceptors.
[124]
 Amines as 
diverse as fluorescein cadaverine and biotin cadaverine can be utilized by gpTGase instead of 
lysine. 
Ting et al. labeled cell surface proteins fused to a “Q-tag” (PKPQQFM) with biotin or Alexa-
568 derivatives of cadaverine using guinea pig liver TGase. The TGase specifically 
recognized the Q-tag of a cadaverine conjugated fluorophore to a glutamine side chain in Q-
rich tag sequences expressed in HeLa cells.
[125]
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EGFR conjugated to a Q-tag was successfully labeled with Biotin cadaverine with no 
impairment in receptor response to EGF.
[125]
 
 
Figure 22 Transglutaminase catalyzed protein modification. Under native conditions TGase 
catalyzes the transamination reaction between Gln and Lys residues in the modified proteins. In TGase 
catalyzed protein labeling, cadaverine functionalized small molecule probe is transferred to a Gln 
residue in the Q tag fused to a protein of interest. POI = Protein of interest, Red star = probe 
 
Phosphopantetheine Transferase (PPTase): The native activity of PPTases is to transfer the 
4‟-phosphopantetheinyl group (Ppant) from CoA to a conserved Ser residue of acyl carrier 
protein (ACP) or peptidyl carrier protein (PCP).
[126]
 Fusion proteins to ACP/PCP can be 
modified with CoA derivatized with a fluorophore or other probes using either AcpS (for 
ACP only)
[126a]
 or Sfp (for both ACP and PCP) (Figure 23).
[127]
 
ACP fused to the N-terminus of neurokinin-1 (NK1) receptor allowed mobility studies down 
to single receptor sensitivity by FRET on cell membranes of HEK293 using Cy3 and Cy5 
fluorophores.
[128]
  
 
Figure 23 Phosphopantetheinyl transferase (PPTase) catalyzed protein modification. PPTases use 
CoA as the source for Ppant and attach it as a phosphodiester to an invariant Ser  residue of the acyl 
carrier protein (ACP) or peptidyl carrier protein (PCP). Fusion proteins to ACP/PCP are labeled by 
CoA derivatized with desired probe. POI = Protein of interest, Red star = probe 
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Sortase mediated site specific labeling: Sortase A (SrtA) from Staphylococcus aureus 
natively catalyzes the hydrolysis of the peptide bond between Thr and Gly in a LPXTG 
recognition motif in the cell surface protein and subsequently forms a new peptide bond 
between the carboxyl group of the exposed Thr and the amino group of the pentaglycine cross 
bridge on the cell surface peptidolglycan thereby anchoring the protein to the cell wall 
(Figure 24).
[129]
 In „Sortagging‟ the SrtA uses biotin and fluorescence probes conjugated to 
peptides with oligo Gly as substrates for modifying the protein of interest fused to the LPETG 
peptide tag.
[130]
 The tag should be located close to the C-terminus of the target protein in a 
flexible region. 
Membrane proteins CD40
[131]
 and osteoclast differentiation factor (ODF)
[130c]
 were labeled in 
intact HEK293T cells.  
 
Figure 24 Sortase mediated ligation of triglycine derivatives to LPXTG tagged proteins. Sortase 
recognizes the LPXTG sequence, cleaves between the Thr and Gly residues and subsequently links the 
carboxyl group of threonine to an amino group of N-terminal glycine oligomers by a native peptide 
bond. POI = Protein of interest, Red star = probe 
 
IV. Small molecule labeling using unnatural amino acids 
Pioneered by Schultz et al., the idea behind the strategy involves the amber suppressor tRNA 
which is chemically modified with an unnatural amino acid by a unique aminoacyl tRNA-
synthetase corresponding to a unique tRNA-codon pair.
[132]
 Several of these unnatural amino 
acids have novel properties which are useful for studying biochemical and cellular functions 
of protein. 
m-acetyl-phenylalanine was site-specifically incorporated into the LamB membrane protein 
and subsequent labeling with hydrazide dyes was carried out.
[133]
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V. Miscellaneous methods 
The HisZiFit, histidine-zinc fluorescent tag is useful for labeling surface-exposed 
hexahistidine-tagged proteins. Surface exposure of a membrane protein, stromal interaction 
molecule (STIM1) from the ER in HEK293 cells was successfully detected with this 
method.
[134]
 
A 13-amino acid peptide that binds to α-bungarotoxin has been successfully used as a tag for 
labeling extracellular domains of proteins of interest, for e.g., membrane trafficking of AMPA 
receptors and a vesicle-associated protein VAMP2 was observed by this method.
[135]
 
Peptide-peptide interaction between the E3 tag (EIAALKE)3 and probe K3  (KIEELEK)3 or K4 
(KIEELEK)4 has been used for specific labeling of cell-surface receptors such as 
prostaglandin EP3β, EGF and β2- adrenergic receptors.[136] 
 
VI. PTS for labeling cell surface proteins 
In protein trans-splicing (see section 1.2), a polypeptide is reconstituted from split halves 
(Figure 25). The semi-synthetic PTS approach (see section 1.5) has earlier been successfully 
applied for labeling cell surface proteins at either their N- or C-terminus using artificially split 
and chemically synthesized intein fragements.
[90a, 90c]
 The present work takes advantage of the 
superior properties of the fastest known naturally split Npu DnaE intein for labeling cell 
surface proteins.
[4]
  
The PTS approach in contrast to other techniques mentioned above allows for the direct 
manipulation of the polypeptide backbone of the protein of interest (POI). Such backbone 
engineering would also be interesting for protein reconstitution or the creation of 
nanostructures in artificial systems. Majority of the earlier methods for cell surface labeling 
only resulted in the attachment of a modified prosthetic group to a particular side chain in the 
tag and are thus not suitable. A tabular comparison of the various advantages and 
disadvantages of each technique is given in  
Table 1. However, such backbone engineering can also be achieved by the Sortase mediated 
ligation.
[130c]
 This reaction is however hampered by the requirement for high concentrations of 
both the substrates and the bond-forming enzyme sortase A. The split intein approach does 
not necessitate an extra enzyme as the PTS reaction is a self-processing reaction. Moreover, 
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the reaction can be virtually traceless because the split intein fragments are removed during 
the process.  
 
Figure 25 Schematic representation of protein trans-splicing. The intein domain is split into two 
pieces that are connected to the flanking extein sequences. The first step comprises of a fast intein 
association whereby the inteins fold into an active conformation. The rate limiting second PTS step 
then excises the intein joining the two extein sequences with a peptide bond. 
 
Table 1 Comparison of various cell surface labeling techniques 
Method Advantage Limitation 
Biarsenical 
dyes 
Small size, stable self-labeling Arsenic toxicity, Cys reduced, dithiols 
required, high background 
DHFR fusion High Specificity DHFR deficient cell lines required 
NTA-His Site-specific, fast and reversible, 
does not require cell fixation 
Low affinity and stability, quenching, 
Ni
2+
 toxicity 
FKBP12 Cell permeable, non-toxic, high 
affinity and selectivity 
Only two types of fluorophores are 
suitable, protein-ligand dissociation 
Oligo-
Asp/Zn
2+
 
Low Affinity Zn requirement, large size 
SNAP-tag 
fusion 
High specificity, minimal 
background, inert,non-cytotoxic 
Large size of hAGT, AGT-deficient 
cell lines required, degradation of 
fusion protein 
Halo-Tag 
fusion 
Endogenous haloalkanes absent, 
easy labeling with both organic 
dyes and inorganic QD‟s 
Very large tag 
Cutinase Low background, easy synthesis  Suicide inhibitors may react with 
endogenous proteins 
BirA 
Labeling 
Endogenous keto-groups absent, 
selective, small size, easy synthesis 
of hydrazides 
Millimolar concentrations of probe 
required 
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Therefore, it is apparent that no one technique is applicable for labeling the large repertoire of 
cell surface proteins. Each technique has its unique benefit and also suffers from certain 
drawbacks and limitations. An appropriate choice of a technique is possible depending on its 
intended use.  
The aim of this work was to modify proteins expressed on the cell surface and facing the 
extracellular environment in a fast and efficient manner. Protein trans-splicing using the 
naturally split Npu DnaE intein from Nostoc punctiforme was the method of choice for this 
purpose because it is currently the fastest known intein with a t1/2 of ~60s.
[49b]
 The split inteins 
remove themselves due to their autocatalytic character which makes ligation of even entire 
protein domains feasible. This technique will also allow the manipulation of the primary 
sequence of the protein sequence in a post-translational manner. The PTS reaction for labeling 
membrane proteins will allow for the rapid and almost traceless modification and the 
additional superior properties conferred by the Npu DnaE intein will allow for its use in 
various applications. 
LpIA labeling High specificity, minimal 
background 
High probe concentrations required 
TGase 
labeling 
Applicable to wide range of 
substrates 
Poor specificity 
ACP/PCP-
Tag 
Tolerates various chemical 
substitutents, specific 
Large size of tag 
Suppressor 
tRNA 
Specificity, versatile, minimal 
structural perturbation, small 
molecule label 
tRNA/synthetase pair for each amino 
acid, endogenous amber codons, low 
suppression efficiency 
HisZiFit Tight affinity Suboptimal dye characteristics 
Sortagging Protein backbone modification Necessity of sortase A and high 
concentration of substrate. 
Protein-trans 
splicing 
Protein backbone modification, 
traceless, autocatalytic 
Size of intein, effect of extein 
sequence 
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2 MATERIAL 
2.1 Apparatus 
 
Table 2 Apparatus list 
Apparatus Manufacturer 
-80 °C freezer New Brunswick scientific ultra low 
temperature freezer 
-152 °C deep freezer SANYO Ultra low temperature freezer, MDF-
1156 
Agarose gel station PEQLAB Perfect Blue Gelsystem M and L 
Weighing balance Mettler PM400; Sartorius Basic 
 Autoclave H+P Laboratory technology Varioklav 135 S 
Chromatographie system GE Healthcare ÄKTA prime plus 
CO2 incubator Thermo Scientific Heraeus Heracell 150 
Agarose and SDS-PAGE gel documentation Canon PowerShot G5 
Electroporator Bio-rad MicroPulser 
Emulsifier Avestin Emulsiflex-C5 
Heating block Eppendorf Thermostat Plus; Eppendorf 
Thermomixer comfort 
Horizontal Shaker Heidolph Promax 1020 
Incubator  Memmert INE 800 
Incubator Shaker Infors HT Aerotron; New Brunswick 
Scientific I26,TC-7 
Microscope Olympus IX-81; Olympus FV100 confocal 
PCR Biometra TPersonal Combi 
pH-meter HANNA instruments pH211 
Pipettes Eppendorf Reference 
Double distilled water Millipore Milli-Q 
Scanner Cannon CanoScan 8400F 
SDS-PAGE Apparatus Bio-Rad Mini-PROTEAN 3 Cell; Bio-Rad 
PowerPac Basic 
Safety hood Nuaire NU 440-500E 
UV-screen H.Saur Transilluminator IL-200M 
UV/Vis-Spectrophotometer GE Healthcare Ultrospec 3100 pro; Varian 
Cary 100Bio 
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Vortex LMS VTX 300 
Waterbath P-D Industriegesellschaft WB20 
Western blot apparatur Bio-Rad Mini Tans-Blot Cell 
Cell density counter GE Healthcare Ultrospec 10 
Centrifuge Eppendorf Centrifuge 5415 D; Eppendorf 
Centrifuge 5804 R; Sorvall Evolution 
 
2.2 Chemicals, Enzymes and Other Instruments 
 
A comprehensive list of the chemicals used in this work is given in Table 3. 
Table 3 Chemical list 
Supplier Product(s) 
AppliChem GmbH (Darmstadt) Glycine, IPTG,Tris 
Becton, Dickinson and Company (New 
Jersey, USA) 
Yeast extract 
Biolegio (Nijmegen, Netherlands) Oligonucleotide 
Carl Roth (Karlsruhe) Acrylamide solution for SDS-PAGE, Agar 
Nr.1, Ampicillin, APS, L-Arabinose, 
Bromophenol blue, BSA, Coomassie Brilliant 
blue R 250, Chloramphenicol, DMSO, 
Ethanol, Ethidium-bromide, Glucose, β-
mercaptoethanol, Milk powder, SDS, 
TEMED; Triton X-100. Tween-20, Visking-
dialysis bag 
Covance (Princeton, USA) Anti-GFP, Anti-HA antibodies 
Eurogentech (Seraing,Belgium) Agarose, Electroporation cuvette 
Eurofins MWG Operon (Ebersberg) Oligonucleotides 
Fermentas (Burlington, Canada) dATP, dTTP, dGTP, dCTP, DTT, DNA and 
Protein marker, T4 DNA-ligse, Restriction 
enzymes 
Finnzymes (Espoo, Finnland) Phusion
TM
 DNA polymerase 
GE Healthcare (Little Chalfont, Great 
Britain) 
ECL and ECL advanced western blotting kit, 
HyperfilmTM ECL, Whatman GB500 
Blotting paper, Anti-cmyc antibody 
IBA (Göttingen) Strep-tactin sepharose, D-desthiobiotin 
Invitrogen (Darmstadt) Quantum dot 655 starter kit (streptavidin 
coated) 
MatTek Corporation (Ashland, USA) 35-mm-glassbottom dish 
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Millipore (Billerica, USA) Sterile filter (45 nm) 
New England Biolabs (Ipswich, USA) Phusion high fidelity DNA-polymerase, 
Restriction enzymes 
PAN Biotech GmbH (Aidenbach) Media, Buffer and Solutions for cell culture 
Qiagen (Hilden) QIAquick PCR-Purification and Gel-
Extraction kit, Ni2+-NTA-Superflow 
Sarstedt (Nümbrecht) 100-mm-cell culture dish, 6 well plates, 
filtration units 
Sigma-Aldrich (St-Louis, USA) EDTA, PEG 3350 
 
2.3 Vectors 
 
2.3.1 pRSFDuet 
 
The pRSFDuet vector (3.8 kb) from Novagen was developed for the co-expression of two 
target proteins. It encodes two MCS each of which is preceded by a T7 promoter, lac operator, 
and a ribosomal binding site. In addition, it also includes the Kanamycin-resistance gene, the 
lacI gene and the replication origin RSF derived from the RSF1030 replicon. In this work, this 
vector was not used for co-expression but for the expression of a single target gene cloned 
into the first MCS. 
2.3.2 pBAD 
 
The pBAD vectors from Invitrogen allow the expression of a protein of interest by the 
addition of L- arabinose. The target gene is under the control of the araBAD promoter at its 
5‟-end which in turn is regulated by the AraC-repressor protein. In addition, for maximal 
expression, the binding of L- arabinose to the AraC-Repressor requires the complex of cAMP 
and cAMP activator protein (CAP). 
2.3.3 pmCherry-N1 
 
The pmCherry-N1 vector (4.7 kb) is derived from the Discosoma sp. red fluorescent protein, 
DsRed. This mammalian expression vector can be used for the localization determination of 
proteins fused in frame to the N-terminus of mCherry-N1 by fluorescence microscopy. The 
inserted gene should contain an ATG-initiation codon with no in-frame stop codons in 
between. The excitation and emission maxima of mCherry is 587 nm and 610 nm, 
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respectively. A CMV promoter upstream of the MCS allows for its expression in mammalian 
cells. The pmCherry-N1 vector can also be used for simply expressing the mcherry protein in 
a cell line and can be easily transfected using any given transfection protocol. It contains the 
gene for conferring kanamycin resistance to E.coli cells. 
2.3.4 pEGFP-N1 
 
The pEGFP-N1 (4.7 kb) vector from Clontech was derived from the wt-GFP containing a 
double amino-acid mutation of Phe-64 to Leu and Ser-65 to Thr. This mammalian expression 
vector can be used for the localization determination of proteins fused in frame to the N-
terminus of pEGFP-N1 by fluorescence microscopy. The inserted gene should contain an 
ATG-initiation codon with no in-frame stop codons in between. The excitation and emission 
maxima of pEGFP is 488 nm and 507 nm, respectively. A CMV promoter upstream of the 
MCS allows for its expression in mammalian cells. The pEGFP-N1 vector can also be used 
for simply expressing the EGFP protein in a cell line and can be easily transfected using any 
given transfection protocol. It contains the gene for conferring kanamycin resistance in E.coli 
cells. Genbank: U55762.1 
2.3.5 pCDNA3 
 
The pcDNA3 vector (5.4 kb) from Invitrogen is a shuttle vector for the expression of proteins 
in mammalian cells. After the cloning of the gene of interest in the multiple cloning site 
(MCS), the expression can occur under the control of the CMV promoter. The vector contains 
an Ampicillin-resistance gene (bla) that serves as a selectivity marker in E. coli. 
2.3.6 pDisplay 
 
The pDisplay mammalian expression vector (5.3 kb) allows for the expression of proteins on 
the cell surface. The gene of interest is fused to the N-terminus of the Ig- chain leader 
sequence, directing the protein to the secretory pathway. At the C-terminus is the 
transmembrane domain of the platelet derived growth factor receptor (PDGFR) which anchors 
the expressed protein to the extracellular side of the plasma membrane. The vector backbone 
also contains the hemagglutinin A (HA) and the myc epitopes for detection by western blot 
and immunofluorescence. 
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2.4 Micro-Organisms and Cell Lines 
 
2.4.1 E.coli Strains 
 
I. DH5α 
This heat competent E.coli strain (Subcloning efficiency 
TM, DH5α TM) was purchased from 
Invitrogen. 
Genotype: F-Φ80lacZΔM15Δ(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rk-,  mk+) phoA 
supE44 thi-1 gyrA96 relA1 λ- 
 
II. XL-10 Gold 
 
This strain was used for preparing electro-competent cells for the purpose of cloning and was 
purchased from Stratagene. 
 
Genotype: Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr) endA1 supE44 thi-1 recA1gyrA96 relA1 
lac Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
 
III. BL21-Gold (DE3) 
 
This strain was used for the preparation of heat competent cells for the purpose of protein 
expression and was purchased from Stratagene. 
 
Genotype: F- ompT hsdS (rB-mB-) dcm+ Tetr gal λ(DE3) endA Hte 
 
 
2.4.2 Eucaryotic Cell Lines 
 
I. Neuro2a : This cell line was derived from the neuroblast cells from mouse brain. 
 They are amoeboid like stem cells and grow as an adherent monolayer. 
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II. COS-7 : This cell line was derived from the kidney of the African green monkey. 
 They are fibroblast-like cells and grow as an adherent monolayer.  
 
III. CHO : This cell line was derived from the ovary of an adult Chinese Hamster. They 
 are epithelial-like cells and grow as an adherent monolayer. 
 
2.5 Growth Media 
 
2.5.1 E.coli Growth Media 
 
LB-media was used as full growth media for E.coli cells. The media was sterilized by 
autoclaving for 30 mins at 121ºC and 1,5 bar. For preparing Agar plates, 1,5 % (w/v) agar-
agar was added to the LB-media before autoclaving. 
 
LB medium:    10  g/L Tryptone 
        5  g/L Yeast Extract 
   5 g/L Nacl 
 
The relevant antibiotic (heat sensitive) was added to the media after autoclaving as a sterile 
filtered solution in the following concentration: Ampicillin (100 µg/mL), Kanamycin (50 
µg/mL). 
 
2.5.2 Mammalian Cell Culture Growth Media 
 
I. Neuro2a: MEM (Minimum Essential Media) from PAN-Biotech was used for the 
 growth of the Neuro2a mammalian cells. 
 
  MEM:     EBSS (Earle‟s balanced salt solution) 
     (including)    2,2  g/L NaHCO3 
  In order to prepare the full growth media, MEM was supplemented with the following 
  components and sterile filtered and then stored at 4 ºC. 
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  MEM:     10 %  (v/v) Fetal Bovine Serum (FBS) 
     (full growth media)    2  mM L-Glutamine 
      100  U/mL Penicillin 
      100   µg/mL Streptomycin 
      1 mM Sodium Pyruvate 
 
II. COS-7: DMEM (Dulbecco‟s Modified Eagle‟s Media) from PAN-Biotech was used 
 for the growth of COS-7 cells 
 
  DMEM:    4,5   g/L Glucose 
     (including)    4 mM  L-Glutamine 
      1 mM   Sodium Pyruvate 
      3,7   g/L NaHCO3 
 
  In order to prepare the full growth media, DMEM was supplemented with the 
 following components and sterile filetered and then stored at 4 °C. 
 
  DMEM:    10 %  (v/v) FBS 
     (full growth media)    2  mM L-Glutamine 
      100  U/mL Penicillin 
      100  µg/mL Streptomycin 
 
III. CHO: Ham‟s F-12 media from PAN-Biotech was used for the growth of CHO cells. 
 
 Hams’ F-12:  1,176   g/L NaHCO3 
     (including)      1  mM Sodium Pyruvate 
  
  In order to prepare the full growth media, HAM‟s –F12 media was supplemented with 
  the following components and sterile filtered and then stored at 4ºC. 
 
  Hams’ F-1:    10 %   (v/v) FBS 
     (full growth media)    2         mM L-Glutamine 
 100 U/mL Penicillin 
  100      µg/mL Streptomycin 
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2.6 Buffers and Solutions 
 
I. Coomassie Staining    40 %   (v/v) Ethanol 
  Solution:     10 %   (v/v) Acetic Acid 
      2,5       g/L Coomassie Brilliant Blue R 250 
 
II. Coomassie Destaining     40 %   (v/v) Ethanol 
  Solution:    10 %   (v/v) Acetic Acid 
 
III. Dulbecco’s Phosphate-  0,2       g/L KCl 
  Buffered saline without  0,2       g/L KH2PO4 
           Ca
2+
 and Mg
2+
 (PBS):     8         g/L NaCl 
      2,2       g/L Na2HPO4·7H2O 
 
IV. EB-Buffer:    10        mM Tris-HCl, pH 8,5 
 
V. Ni
2+
-NTA-Buffer A:   50        mM Tris/HCl, pH 8,0 
                                                                       300       mM NaCl 
 
VI. Ni
2+
-NTA-Buffer B:   50        mM Tris/HCl, pH 8,0 
               300        mM NaCl 
 
VII. SDS-Gel Running    25        mM Tris 
  Buffer:    250      mM Gylcine 
      0,1 %  (w/v) SDS 
VIII. 4x SDS- Loading   50        mM Tris/HCl, pH 6,8 
  Buffer:     8 %    (w/v) SDS 
      40 %   (v/v) Glycerol 
      20 %   (v/v) β-Mercaptoethanol 
       5          mg/L Bromphenolblau 
 
IX. Strep-Tag Buffer W:  100      mM Tris/HCl, pH 8,0  
     150      mM NaCl 
      1         mM EDTA 
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X. Strep-Tag Buffer E:   100      mM Tris/HCl, pH 8,0 
      150      mM NaCl 
  1         mM EDTA 
   2,5      mM D-Desthiobiotin 
 
XI. Western blot       3        g/L Tris 
  Running Buffer:   14,4     g/L Glycine 
      150      mL Methanol (for 1L) 
 
XII. TBST-Buffer:   50        mM Tris/HCl, pH 7,6 
      150      mM NaCl 
      0,1 %   (v/v) Tween-20 
 
XIII. TE-Buffer:    10        mM Tris/HCl pH 8,0  
     1        mM EDTA  
 
XIV.   Amylose re-suspension                      20       mM Tris/HCl, pH 7,4 
 Buffer:    200     mM NaCl 
   1        mM EDTA 
 
XV. Amylose Elution   20       mM Tris/HCl, pH 7,4 
  Buffer:     200     mM NaCl 
    1        mM EDTA 
    10       mM Maltose 
 
XVI. Agarose gel     89       mM Tris 
  Running buffer   89       mM Boric Acid 
  (TBE):    0,02    mM EDTA (0,5 M) 
 
XVII. Bradford’s solution:   0,1      mM Coomassie Brilliant Blue G 250 
      25       mL Ethanol 
      50       mL Phosphoric Acid (85 %) 
      For 500 mL solution 
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3 METHODS 
 
3.1 General Molecular Biology Methods 
 
Standard molecular biology techniques were used for this work. These methods include: 
plasmid preparation from E.coli, DNA-amplification with polymerase chain reaction (PCR), 
DNA-fragment and plasmid purification with QIAquick-spin colums from Qiagen, ligation of 
DNA fragments using T4-DNA ligase as well as sequencing of all plasmid constructs from 
GATC Biotech AG (Constanz). A detailed account of these methods including the 
transformation of competent E.coli cells with plasmid-DNA can be found in the following 
book of protocols.
[137]
 A list of all of the constructs used in this work is given in Table 4. 
3.1.1  Bacterial Expression Plasmids 
 
The source of various bacterial plasmids used in this work is given below in the order in 
which they appear in the text.  
Construct 2 (pVS07; ST-EGFP-NpuDnaE
N
), Construct 4 (pVS18; ST-EGFP-NpuC1SDnaE
N
) 
and Construct 5 (pVS01, NpuDnaE
C
-Trx-His6) were kindly provided by Vivien Schütz and 
have been previously reported.
[49b]
 
Construct 8 (pTD060, MBP-NpuDnaE
N
-His6): The NpuDnaE
N
-His6 sequence was amplified 
from plasmid pVS24 (kindly provided by Vivien Schütz), ST-Ald Tag-NpuDnaE
N
-His6 using 
primers oTD048 FP 5‟- ATA GAA TTC TGT TTA AGC TAT GAA ACG GAA ATA TTG -
3‟and oTD048 RP 5‟- TAT AAG CTT AGT GGT GGT GGT GGT GGT GCT C -3‟. The 
product obtained was double digested with EcoRI / HindIII and cloned downstream of the 
MBP sequence of the pSTDuet vector of plasmid pVS22 (kindly provided by Vivien Schütz) 
encoding MBP-TEV-NpuDnaE
N
 (Arg mutant)-His6, resulting in plasmid pTD060. 
Construct 9 (pAU07, NpuDnaE
C
-EGFP-His6) and Construct 10 (pAU08, ST-gpD-Npu 
DnaE
N
) were obtained from a previous work of Annika Urbanek and have been previously 
reported.
[49b]
 
Construct 12 (pJZ68, NpuDnaE
C
-gpD-His6) was provided by Dr. Joachim Zettler. 
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Construct 14 (pTD043, ST-PCP-NpuDnaE
N
) and Construct 15 (pTD040, NpuDnaE
C
-PCP-
His6) were prepared by bachelor student Christina Geraldine Kantzer.
[138]
 
3.1.2 Mammalian Expression Plasmids 
 
Construct 1 (pTD038; Igκ-HA-NpuDnaEC-Trx-His6-myc-TMD-mCherry): The mCherry-N1 
encoding gene was PCR amplified from plasmid mCherry-N1 using the following primers: 
forward primer oTD032 FP 5‟- ATA GCT AGC ATG GTG AGC AAG GGC GAG GAG G -
3‟; reverse primer oTD032 RP 5‟- TAT GCG GCC GCT ACT TGT ACA GCT CGT CC -3‟. 
The product obtained was double digested with NheI /NotI and cloned downstream of the 
PDGFR trans membrane domain (TMD) encoding sequence of the p-Display vector of 
plasmid pTD036 (obtained from Dr.Leif Dehmelt) encoding Igκ-HA-SNAP tag-myc-TMD-
EGFP-N1, resulting in plasmid pTD037 coding for Igκ-HA-SNAP tag- myc-TMD-mCherry-
N1. In a second step, the gene fragment encoding NpuDnaE
C
-Trx-His6 was amplified using 
PCR from bacterial plasmid NpuDnaE
C
-Trx-His6 (pVS01) using the following primers: 
forward primer oTD018 FP 5‟- ATA GGG CCC AGA TGA TCA AAA TAG CCA CAC 
GTA AAT -3‟; reverse primer oTD018 RP 5‟- TAT GTC GAC GTA GTG ATG GTG ATG 
GTG ATG AGA -3‟. The PCR product obtained and plasmid pTD037 were digested with 
ApaI/SalI and ligated to yield the mammalian expression plasmid pTD038. 
Construct  3 (pTD056; Igκ-HA-NpuDnaEC(C+1S)-Trx- His6-myc-TMD-mCherry): The C+1S 
mutant gene fragment was PCR amplified from bacterial plasmid NpuDnaE
C
(C+1S)-Trx-His6 
(pVS08) using the following primers: oTD018 FP forward primer 5‟- ATA GGG CCC AGA 
TGA TCA AAA TAG CCA CAC GTA AAT -3‟; reverse primer oTD018 RP 5‟- TAT GTC 
GAC GTA GTG ATG GTG ATG GTG ATG AGA -3‟. The resulting sequence and vector 
plasmid pTD038 were double digested with Apa1/Sal1 and ligated to obtain the construct 
pTD056. 
Construct  6 (pTD058; Igκ-HA-NpuDnaEC-myc-TMD-mCherry): The gene fragment coding 
for NpuDnaE
C
 was amplified from plasmid pVS01 using primers oTD047 FP forward primer 
5‟- ATA GGG CCC TGA TGA TCA AAA TAG CCA CAC GTA AAT ATT TAG -3‟ and 
oTD047 RP reverse primer 5‟- TAT GTC GAC ATT GAA ACA ATT AGA AGC TAT G -3‟ 
and double digested with ApaI/SalI and further ligated into plasmid pTD038 which was also 
digested with the same enzymes. 
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Construct 7 (pTD061; Igκ-HA-gpD-NpuDnaEC-myc-TMD-mCherry): The gene fragment 
coding for gpD-NpuDnaE
C
 was amplified from plasmid pVS05 (ST-gpD-NpuDnaE
C
-His6) 
using primers oTD050 FP forward primer 5‟- ATA GGG CCC AGG CGA GCA AAG AAA 
CCT TTA C -3‟ and oTD050 RP reverse primer 5‟- TAT GTC GAC ATT GAA ACA ATT 
AGA AGC TAT GAA GCC -3‟ and double digested with ApaI/SalI along with vector 
pTD038 and was ligated into the vector to yield plasmid pTD061. 
Construct 11 (pTD020; Igκ-HA-ST-EGFP-NpuDnaEN-myc-TMD): The gene fragment coding 
for ST-EGFP-N1-NpuDnaE
N
 was amplified from plasmid pVS07 using primers oTD017 FP 
forward primer 5‟- ATA GGG CCC AGA TGG CCA GTT GGA GC -3‟ and oTD017 RP 
reverse primer 5‟- TAT GTC GAC TTA ATT CGG CAA ATT ATC AAC CCG -3‟. The 
PCR amplified product obtained and the pDisplay vector were double digested with ApaI/SalI 
and the insert was ligated in frame into the vector between the HA-tag and the myc-tag 
sequences resulting in plasmid pTD020. 
Construct 13 (pTD057; Igκ-HA-NpuDnaEC-Trx-His6-myc-Gas1p): The gene fragment coding 
for the Gas1p sequence was amplified using PCR from mammalian expression plasmid 
pCDNA 3.1/Zeo Kre-Prp-Gas1p (kindly provided by Prof. Martin Engelhard and Dr. Miria 
Schumacher), using the following primers: oTD045 FP forward primer 5‟- ATA GTC GAC 
TCT TCT TCT TCT TCT TCA GCT TCA TC -3‟; oTD045 RP reverse primer 5‟- TAT GCG 
GCC GCT TAA ACC AAA GCA AAA CCG AC -3‟. The resulting PCR product and 
plasmid pTD038 were digested with SalI/NotI and ligated to yield the plasmid pTD057. 
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Table 4 List of constructs  
Construct  Sequence 
1 Igκ-HA-Int
C
-Trx-Myc-TM-mCherry 
2 ST-EGFP-Int
N
 
3 Igκ-HA-Int
C
(C+1S)-Trx-Myc-TM-mCherry 
4 ST-EGFP(C1S)-Int
N
 
5 Int
C
-Trx-His6 
6 Igκ-HA-Int
C
-Myc-TM-mCherry 
7 Igκ-HA-gpD-Int
C
-Myc-TM-mCherry 
8 MBP-Int
N
-His6 
9 Int
C
-EGFP-His6 
10 ST-gpD-Int
N
 
11 Igκ-HA-ST-EGFP-Int
N
-Myc-TM 
12 Int
C
-gpD-His6 
13 Igκ-HA-Int
C
-Trx-Myc-GPI 
14 ST-PCP-Int
N
 
15 Int
C
-PCP-His6 
 
3.2 Protein Expression and Purification 
 
3.2.1 Recombinant Protein Expression in E.coli  
 
Recombinant protein production was carried out by transforming the bacterial strain E.coli 
BL21 (DE3) with the desired plasmid. Test expressions were carried out in 4 mL of LB-
medium. Samples were collected before and after induction and analyzed on an SDS-Page. 
For carrying out preparative scale protein production, 300-800 mL of LB-medium containing 
the relevant antibiotic in the required concentration (50 µg/mL Kanamycin,100 µg/mL 
Ampicillin), to maintain selection pressure, was inoculated with an overnight E.coli 
expression culture at a ratio of 1:100. The cells were grown at 37 ºC under 250 rpm 
conditions to an O.D.600 of 0.5-0.7. At this point the temperature was lowered to 28 ºC and 
protein expression was induced by adding either 0.4 mM IPTG or 0.02-0.2 % Arabinose and 
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the cells were grown for an additional 4-5 hours. After expression, the cells were harvested by 
centrifugation (8000 rpm, 20 min, 4 ºC) and the pellet was re-suspended in a small volume of 
the appropriate buffer and stored at -20 ºC. 
3.2.2 Cell Lysis 
 
Cell lysis is the release of the expressed proteins from E.coli. An EmulsiFlex 
®
-C5 high 
pressure homogenizer was used for this purpose. The device was pre-cooled with ice in order 
to prevent the proteins from being digested. The resuspended cells were thawed and then 
passed under high pressure through a small opening till a pressure difference of 6.9 MPa was 
reached. The resulting shear forces thereby destroyed the cell walls and released the proteins 
present in the cytosol. In order to achieve the most complete disruption, the cell suspension 
was passed twice through the homogenizer. To separate the cell lysate from the cell debris 
and insoluble proteins, the suspension was centrifuged for 30 min at 17,000 rpm and 4 °C. 
The clear supernatant was used directly for the specific affinity chromatography. 
3.2.3 Protein Purification 
 
The purification of the proteins was carried out by utilizing the N-and/or C-terminal fusion 
affinity tags. In this work, the affinity tags used were the hexahistidine sequence (H6), the 
Strep-tag II (ST) and the Maltose Binding protein (MBP). The exact steps were performed 
based on the information provided with the column material by the manufacturer. For the 
affinity chromatography on immobilized Nickel ion for proteins fused with a H6-tag, material 
from Qiagen (Ni
2+
-NTA Superflow) was used. Proteins fused with a Strep-tag II were purified 
with the Strep-Tactin Sepharose material obtained from iBA. The Amylose resin for purifying 
proteins fused with a MBP-tag was obtained from NEB.  
3.2.4 Protein Purification under Denaturing Conditions 
 
Recombinant Int
C
-fusion proteins from construct 3 (NpuDnaE
C
-Trx-His6) and construct 9, 
(NpuDnaE
C
-EGFP-His6) and construct 14 (NpuDnaE
C
-PCP-His6) were known to undergo 
proteolysis and therefore cell lysis was performed in the presence of buffer containing 8 M 
urea and subsequent Ni
2+
-NTA purification under denaturing conditions was performed. After 
protein expression, the cells were harvested by centrifugation (8000 rpm, 20 min, 4 ºC) and 
the pellet was frozen at -80 °C. The cells were later thawed and re-suspended in Ni
2+
-NTA 
buffer A containing 8 M urea. Post addition of 8 M urea containing buffer, all steps were 
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performed under room temperature conditions. Cell lysis was performed and the cells were 
further harvested by centrifugation at 10,000 rpm, 30 min, R.T. The supernatant was directly 
used for protein purification using the His6-tag at the C-terminus of the protein. Purified 
protein was dialysed against PBS buffer containing 10 % glycerol. 2 mM DTT was added to 
the dialysis buffer unless otherwise mentioned in order to keep the protein in the reduced 
form. 
2 mL of Ni
2+
-NTA agarose material was added to the column and was equilibrated with Ni
2+
-
NTA buffer A containing 8 M urea. The clear supernatant was passed through the column 
once and the flow through was collected. Washing was performed stepwise by initially 
washing with 5 column volumes of Ni
2+
-NTA buffer A containing 20 mM imidazole and 8 M 
urea and further a second washing step was performed using 5 column volumes of Ni
2+
-NTA 
buffer A containing 40 mM imidazole and 8 M urea. Elution was carried out by the addition 
of 5 column volumes of Ni
2+
-NTA buffer A containing 250 mM imidazole and 8 M urea. 
Elution fractions were collected and dialysed against PBS buffer containing 10 % glycerol. 
2 mM DTT was added to the dialysis buffer unless otherwise mentioned in order to keep the 
protein in the reduced form. 
3.2.5 Calculation of Protein Concentration 
 
The concentration of a purified protein was calculated by measuring its absorbance at λ = 280 
nm in solution. The extinction coefficient was calculated by using the software program 
Protean (DNAstar). This photo metric calculation was performed in a quartz cuvette using a 
Ultrospec 
TM
 3100 pro UV/Vis spectrophotometer. The purified protein was further aliquoted 
and flash frozen under liquid N2 conditions. The aliquots were stored at -80 °C. 
3.2.6 PCP-Labeling by Sfp PPTase 
 
Labeling of the PCP-domain was carried out in the following manner. To 5-20 µM of the PCP 
fusion construct dissolved in PBS buffer, 10 mM MgCl2 was added along with 40 equivalents 
of CoA-derivatized with either tetramethylrhodamine (TMR) or Dylight 488. To this, 0,02 
equivalents of the Phosphopantetheinyl transferase (PPTase) Sfp purified from Bacillus 
subtilis was added and the reaction mixture was incubated at 4 °C overnight. Excess of CoA 
was removed via dialysis against PBS buffer.  
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3.2.7 In vitro Trans-Splicing Reaction 
 
Purified Npu DnaE intein fusion proteins were added in equimolar concentration ranging from 
10-20 µM in PBS buffer (DMEM wherever mentioned) and incubated at 37 °C. To each 
reaction mixture 2 mM DTT was added from a freshly made stock. At various time points 
aliquots were collected and the reaction was stopped by adding 4x SDS-loading buffer. For 
the 0 h sample, 4x SDS- loading buffer was added to the first construct and the mixture was 
boiled for 5 min and the partner protein was then further added to this sample. The reaction 
was followed on an SDS-PAGE gel. All reactions were performed at least in duplicate. 
In case of reactions under non-reduced conditions DTT was either completely omitted or one 
partner protein was first reduced with DTT and the excess DTT was removed via dialysis 
against PBS buffer. In the latter case, protein trans-splicing was performed with the second 
partner construct being non-reduced and in the absence of DTT. 
 
3.3 Mammalian Cell Culture Techniques 
 
3.3.1 Passaging of Cells  
 
Mouse Neuro-2a cells were cultured in 12 mL of full growth MEM at 37 ºC under 5 % CO2 in 
a 100 mm cell culture dish and passaged after every 48 h. At this point, when the cells were 
70-80 % confluent, the old media was removed and the cells were washed once with 5 mL of 
prewarmed 1x sterile DPBS. 1 mL of pre-warmed Trypsin/EDTA solution was added drop-
wise to the cells and the cells were incubated for 5 min at 37 ºC, 5 % CO2. 6 mL of fresh pre-
warmed full growth MEM was added to the cells to de-activate trypsin and the cells were 
washed thoroughly to detach them from the culture dish. 1 mL from this solution was then 
plated on 12 mL of full growth MEM on a fresh culture dish and the cells were incubated for 
a further 48 h. 
CHO cells were cultured as described above with HAM‟s F-12 full growth media and COS-7 
cells were cultured in DMEM full growth medium. 
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3.3.2 Transfection 
 
Transfection was carried out using Gene Juice transfection reagent according to the following 
protocol. 1x10
5 
cells were plated on either a 35 mm glass bottom mat-tek dish or a 6 well-
plate one day before transfection. 24 hours post cell plating, a 100 µL transfection mixture 
was prepared/dish, in an eppendorf cup, containing 1µg DNA, 4 µL gene juice transfection 
reagent and the remaining of serum free DMEM media. A master mix was prepared in case of 
several transfections and volumes were adjusted accordingly. 
For expression plasmids encoding for proteins which could not be observed by simple 
fluorescence microscopy, 0,1 µg of mCherry-N1/EGFP-N1 was co-transfected along with 
0,9 µg of the plasmid DNA. mCherry-N1/EGFP-N1 was also used in a concentration of 0,1 
µg as transfection control and the transfection mixture volume was adjusted accordingly. 
3.3.3 Fixation  
 
Fixation of cells was either carried out directly after 24 h of transfection with the required 
construct in case of cells expressing a non-fluorescent fusion protein in order to observe its 
expression and targeting or post trans-splicing with an exogenously added recombinant 
protein. Fixation was performed by completely removing the growth media and then washing 
the cells twice with pre-warmed 1x DPBS. 1mL of fixing solution (1 mL 37 % HCHO + 8 
ML 1x DPBS) was added to the cells and incubation was carried out for 20 min at 37 °C. 
Cells were then again washed 3 times with 1x DPBS to remove all traces of formaldehyde and 
1mL of 1x DPBS was finally added. Cells were either directly observed with confocal 
microscopy or stored at 4 °C for later use.  
3.3.4 Immunostaining 
 
The immunostaining reactions were carried out on cells plated on glass bottom Mat-tek dishes 
for carrying out confocal microscopy. Post transfection, cells were fixed with 1 mL of fixing 
solution for 20 min at 37 °C. Washing was carried out 3 times with DPBS and the cells were 
either permeablized with 1 mL permeablization solution or taken for further processing. The 
permeablization reaction was carried out for 15 min at room temperature. The permeabilized 
cells were then washed 3 times with DPBS. In the next step, blocking was carried out using 
150 μL of blocking solution and incubating for 1 h at 37 ºC. Blocking solution was replaced 
with either 250 μL of anti-HA or anti-MBP monoclonal primary antibody, used at a dilution 
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of 1:500 in antibody dilution solution. Cells were incubated at for 1 h, 37 ºC and then washed 
3 times with DPBS. 250 μL of goat anti-mouse secondary antibody tagged with either Alexa-
fluor 568 or Alexa- fluor 488 was used at a dilution of 1:1000 in antibody dilution solution 
and added to the cells and again an incubation of 1h at 37 ºC was carried out. The cell layer 
was again washed with DPBS 3 times and finally 1 mL of DPBS was added to prevent the 
cell layer from drying. The cells were either stored at 4 ºC for later use or directly observed 
using an Olympus fluoview (FV) 1000 confocal laser microscope. GFP excitation maxima 
occurs at ~508 nm and therefore the 488 nm line of argon laser was chosen for excitation. The 
568 nm line of krypton laser was used for exciting mCherry-N1 showing an excitation 
maxima at ~610 nm. The cells were viewed using the 63x oil immersion objective lens. 
3.3.5 Protein Trans-Splicing on Living Cells 
 
1 x 10
5
 Neuro-2a cells were plated on 35 mm glass bottom mat-tek dishes or 6 well-plates, as 
required, and incubated at 37 ºC and 5 % CO2. 24 h post plating, when the cells were 70-80 % 
confluent, they were transfected with the relevant construct and incubated for another 24 h. 
mCherry-N1 was transfected separately as a negative control for the experiments. For 
experiments with construct 11, EGFP-N1 was used as a negative control. Expression and 
targeting of fluorescently tagged fusion proteins was directly observed by fluorescence 
microscopy. In case of cells expressing a non-fluorescent fusion protein, (construct 13) 
mCherry-N1 was co-transfected as a transfection control.  
For the trans-splicing experiment a mixture of 5 μM protein, 2 mM DTT and the remaining of 
serum-free DMEM was made in an eppondorf cup to a final volume of 300 μL/dish or /well. 
Volumes were adjusted accordingly. 24 h post-transfection, the cells were washed once with  
1 mL of serum-free DMEM. The splicing reaction was carried out by incubating the cells with 
300 µL of the reaction mixture at 37 ºC for 1 h, unless otherwise stated. After the incubation 
the cells were washed 2-3 times with serum-free DMEM to remove excess of protein. 
Fixation was carried out by adding 1 mL of fixing solution as mentioned above under caption 
3.3.3. The cells were further washed 3 times with DPBS and finally 1 mL of DPBS was added 
to the cells to prevent the cell layer from drying. The cells were either immediately analysed 
by confocal microscopy or stored at 4 °C for later analysis. 
For trans-splicing on the surface of COS-7 cells serum free DMEM was used but for CHO 
cells the DMEM media was replaced with serum-free HAM‟s-F12 media. 
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3.3.6 Western Blot Analysis 
 
1x10
5
 Neuro-2a cells were plated on each well of a 6 well-plate. The cells were incubated for 
24 h at 37 ºC and 5 % CO2. After 24 h, they were transfected with the relevant expression 
plasmid and again incubated for 24 h to allow for protein expression. Transfection and protein 
expression were confirmed by fluorescence microscopy. Further, trans-splicing on the cell 
surface was performed as mentioned above in section 3.3.5. Post splicing, the cells were 
washed 3 times with serum-free medium. Following washing, 100 μL of 2x SDS-loading 
buffer was added to the cells drop-wise. The cells were thoroughly scraped off from the plates 
and boiled for 10-15 min. The protein samples were separated on a SDS-PAGE gel and 
transferred onto a PVDF membrane for western blotting. Western blotting was carried out 
using the Amersham ECL
TM 
advanced western blotting kit. Detection of protein bands was 
carried out using relevant antibodies-anti-GFP (1 mg/mL; mouse IgG1, Covance, 1:10,000 
dilution), anti-MBP (1 mg/mL; murine IgG2a, Fermentas, 1:25,000 dilution), anti-HA (1 
mg/mL; mouse IgG1, Covance, 1:10,000 dilution), anti-cmyc (1:10,000). Anti-mouse 
antibody (Ig-HRP conjugate, GE healthcare, 1:100.000) was used as the secondary antibody 
for the western blot procedure in all cases. 
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4 RESULTS 
Proteins present on the surfaces of cells are involved in several crucial cellular processes such 
as signalling, differentiation, growth, adhesion and cell-cell communication. A number of 
strategies have been recently developed (see introduction 1.6) for the investigation of the 
structure, function and cellular localization as well as protein-protein interactions of such 
proteins by enabling protein manipulations without loss of protein function. As the surfaces of 
cells are freely accessible, labeling them with synthetic probes is an attractive strategy for 
their functional characterization. In this work, protein trans-splicing (PTS) using the naturally 
split Npu DnaE intein was used for modifying cell surface proteins. 
A protein of interest (POI) on the cell surface can be modified with virtually any 
fluorophore/molecule if a PCP-domain is fused as the extein sequence. The PCP-domain can 
be loaded with a Co-A derivatized molecule and the PTS system will result in a labeled POI.  
In addition, in this work a strategy for performing PTS on the surface of quantum dots has 
also been presented. This would allow for the labeling of any POI with these inorganic 
nanocrystals. 
 
4.1 Proof of Principle Experiments (expression and targeting to the 
plasma membrane) 
For splicing to be performed on the cell surface, the Npu DnaE
C 
fragment was required to be 
presented on the extracellular cell surface. Therefore, expression and secretion of construct 1 
to the plasma membrane was the required first experiment.  
Proteins are targeted to the various compartments of the cell (e.g. nucleus, plasma membrane, 
mitochondria etc.) by a mechanism called protein sorting.
[1]
 This targeting information is 
contained in the protein sequence itself as a signal peptide or a signal sequence usually 
present at the N-terminus of the protein. In case of the plasma membrane, this signal peptide, 
which consists of a few amino acids (3-60 AA) acts as a recognition sequence and targets the 
protein to the secretory pathway. After being synthesized in the cytosol, it is transported into 
the endoplasmic reticulum where the signal sequence is cleaved off. This protein then gets 
further processed in the golgi apparatus and finally ends up in vesicles which fuse to the 
plasma membrane, thereby exposing the protein to the extracellular surface. 
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In this work, the murine Ig-κ chain leader sequence[139] is fused to the N-terminus of the 
protein of interest (POI), targeting the protein for secretion. The transmembrane domain of the 
Platelet Derived Growth Factor receptor (PDGFR-TM)
[140]
 anchors the secreted protein to the 
plasma membrane for display. Additionally, mCherry-N1 was fused to the C-terminus of the 
PDGFR-TM in construct 1 (pTD038, Igκ-HA-NpuDnaEC-Trx-His6-myc-TMD-mCherry), 
enabling the direct visualization of the expressed protein at the plasma membrane by 
fluorescence microscopy. 
Immunostaining (section 3.3.4) against the HA-tag was additionally performed for 
confirmation of protein expression and secretion. Alexa fluor 488 tagged secondary antibody 
was used for detection of the HA-tag. It was clear from the microscopy data obtained (Figure 
26) that targeting of construct 1 to the cell membrane of transiently transfected mouse N2a 
cells was successful. Although most of the fluorescence was observed at the membrane, high 
fluorescence intensity was also detected in the intracellular compartments. 
It was noteworthy that cells transfected with construct 1 and permeabilized with Triton X-100 
did not show significant amounts of intracellular staining with Alexa-488. This suggests that 
maybe the hemeagglutinin sequence is not being fully recognized by the anti-HA antibody. It 
could also result from a cleavage of the independently folding mCherry domain. Another 
reason could be the degradation of the N-terminal HA-Int
C
 sequence. Nevertheless, the 
recognition of the Alexa fluor 488 tagged HA-antibody on the plasma membrane was an 
indication of significant amounts of protein undergoing proper folding in the secretory 
pathway and being displayed on the plasma membrane.  
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A 
 
B          C 
           Non-permeabilized      Permeabilized 
 
Figure 26 Sequence and confocal microscopy images of construct 1 (pTD038). A) DNA sequence 
representing constructing 1 is shown. Igκ = Murine chain leader sequence, HA = hemagglutinin, IntC = 
Intein C-terminal half, Trx = Thioredoxin, Myc = myc epitope, TM = Platelet Derived Growth Factor 
receptor transmembrane domain, mCh = mCherry. 1 was transfected into neuro-2a cells and the cells 
were fixed 24 h later. Membrane targeting was confirmed both by mCherry-N1 fluorescence observed 
at the plasma membrane (red channel) as well as immunostaining against the HA-tag with Alexa-fluor 
488 (green channel). B) non-permeabilized cells. C) Cells permeabilized post fixation with 0.25 % 
Triton X-100. 
 
The next step would be splicing a recombinantly produced Npu DnaE
N
 fusion protein to the 
above expressed protein. 
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4.2 Protein Trans-Splicing on Cell Surface 
Immunostaining experiments confirmed the display of construct 1 on the cell surface. Test for 
splicing activitity would require splicing a target protein/ peptide onto the membrane. EGFP 
was chosen as the protein of interest due to its stability and its autofluorescent nature which 
would allow direct observation of the splicing reaction by fluorescence microscopy. This was 
based on the hypothesis that only cells transfected and expressing construct 1 would also get 
labeled with EGFP after PTS. The scheme of this reaction is shown in Figure 27A and B.  
Cells were transfected with expression plasmid 1 and the splicing reaction was carried out by 
adding protein 2 (VS07; ST-EGFP-NpuDnaE
N
) under the reaction conditions mentioned 
earlier. The reaction was carried out in serum free media in order to avoid interference from 
the components present in FBS. Post washing, cells were observed for splicing activity by 
confocal fluorescence microscopy. For a complete list of reaction conditions see methods 
section 3.3.5 
EGFP fluorescence was clearly observed on the surface of cells transfected with construct 1 
as seen in (Figure 27C). The red (mCherry-N1) and the green (EGFP-N1) fluorescence 
overlap each other to produce the yellow colour. In contrast to this, untransfected cells and 
cells expressing lower levels of the Int
C
 fusion protein did not show any significant green 
fluorescence. On cells transfected with only the control plasmid (cytoplasmic mCherry-N1), 
no green fluorescence was detected (Figure 27D). Furthermore, this control experiment 
indicated a very low unspecific binding of the Int
N
 fragment to the cell surface.  
This data indicated a clear interaction between the split intein halves and hinted at PTS. 
However, split intein fragment association is known to be extremely stable and therefore it 
was concievable that this interaction could be only associated intein fragments. To rule out 
this possibility the logical next experiment was immunoblotting to definitely prove splice 
product formation. 
 
 
 
 
 Results  
64 
A           B 
 
C          D  
      Splicing              Control 
 
Figure 27 Protein trans-splicing on cell surface. A) Schematic representation of PTS on cell surface. 
The Int
C
 fusion protein is targeted and anchored to the plasma membrane with a transmembrane 
domain (shown in orange) with the Int
C
-fragment facing the extracellular environment. The Int
N
 fusion 
protein is recombinantly expressed and purified from E-coli cells and exogenously added onto the cell 
surface. Splicing results in the C-extein and N-extein being ligated together by a peptide bond and the 
intein getting removed. B) Fusion constructs involved in the splicing reaction along with the molecular 
weight of the constructs and splice product formed. C) Neuro-2a cells were transfected with the 
relevant expression constructs. 24 h later the cells were washed and protein 2 was added exogenously 
and the reaction was allowed to continue for 1 h. Post washing, the cells were fixed and visualized by 
confocal microscopy. Cells transfected with and expressing construct 1 at the plasma membrane and 
reacted with protein 2. D) Cells transfected with control construct cytoplasmic mCherry-N1 and 
reacted with protein 2. SP = splice product 
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4.3 Confirmation of Splice Product Formation 
From the microscopy data obtained in the previous experiment, it was evident that the Int
N
 
and the Int
C 
fragments indeed associate with each other. This complex has been described as 
very stable (survives SDS treatment) and therefore could account for the observed co-
localization. However, this non-covalent complex dissociates under 5 min boiling 
conditions.
[51]
 Taking advantage of this fact, a western blot analysis of a cell lysate using the 
anti-GFP antibody was performed to rule out the possibility of intein association.  
Neuro-2a cells were transfected with construct 1 and reacted with protein 2. Post splicing and 
washing, the cells were lysed by treating with SDS and boiled for 10 min. The samples were 
further processed for immunoblot analysis. The immunoblot showed a new band at ~77 kDa 
corresponding to the calculated weight of the splice product (SP 1+2) (Figure 28). This was 
clearly indicative of a covalent bond formation between the extein sequences. This band was 
absent in the control experiment where the EGFP-Int
N
 half was reacted with cells expressing 
only cytoplasmic mCherry-N1. It was also absent from the lysate obtained from cells 
expressing construct 1 but not reacted with protein 2.  
A second, high intensity band was observed at the height of ~40 kDa. It was believed to be 
the excess EGFP-Int
N
 fragment by molecular weight analysis (40.6 kDa) and was only 
observed in those lanes where the cells had been exposed to the Int
N
 fragment.  
 
Figure 28 Anti-GFP western blot for confirmation of splice product formation. Neuro-2a cells 
were transfected with construct 1 and after 24 h these cells were reacted with protein 2. After washing, 
2x SDS containing buffer was added for lysis and the cells were further processed for immunoblotting. 
Control experiments were performed with cells transfected with mCherry-N1, SP = splice product 
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Thus, formation of splice product indeed occurred on the cell surface indicative of a 
successful PTS reaction. Further characterizations with splice mutants were required to fully 
demonstrate PTS on the membrane surface. 
 
4.4 Effect of Mutations on Protein Trans-Splicing 
To fully authenticate the occurrence of a reaction, it is imperative to show absence of or 
anomalous behaviour with a mutant. This proves that the given reaction is specific and occurs 
only under wild type conditions. Therefore, to confirm that the data obtained was indeed due 
to trans-splicing, similar splicing experiments were performed on the cell surface with splice 
mutants.  
The „CFN‟ tripeptide at the C-terminal splice junction of the DnaE intein corresponds to the 
first 3 amino acids of the C-extein sequence.
[49]
 In construct 3 the catalytic +1Cys was 
replaced by Ser. For the Npu DnaE intein, this Cys residue is responsible for the nucleophilic 
attack on the linear thioester to form the branched intermediate (see introduction section 1.2). 
In vitro experiments with this mutant construct had resulted in only marginal splice product 
formation.
[49b]
 
N2a cells were transfected with the splice mutant 3 (pTD056; Igκ-HA-NpuDnaEC(C+1S)-Trx- 
His6-myc-TMD-mCherry) and trans-splicing was performed with protein 2 on the cell 
surface. The scheme of this reaction is shown in Figure 29A. Post washing, confocal 
fluorescence microscopy was performed and the results obtained with this splice mutant are 
shown in Figure 29B. 
The expression level of construct 3 in the cells was similar to that obtained for construct 1 and 
it was processed via the secretory pathway and targeted to the plasma membrane. EGFP green 
fluorescence after addition of protein 2 was visible on the surface of the transfected cells. 
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A       B 
 
Figure 29 Protein trans-splicing using splice mutant 3. A) Schematic representation of the protein 
trans-splicing reaction on the cell surface using splice mutant 3. In this construct the first amino acid 
of the C-extein, Cys, was mutated to a Ser by site directed mutagenesis. B) Confocal microscopy 
images of the splice mutant (red channel) and the reaction with protein 2 (green channel). SP = splice 
product 
 
In another construct, a point mutation was introduced at the N-terminal splice junction where 
the Cys1 was mutated to Ser (Figure 30A). This Cys is the first amino acid of the Npu DnaE 
intein and acts as a nucleophile in the first step of the splicing mechanism by attacking the 
peptide bond at the Ext
N
-Int
N
 junction (see introduction 1.2). It was known from earlier in 
vitro experiments with this intein that a Cys1Ala mutation completely abolished splicing.
[49b]
 
Also, similar results were obtained with the Ssp DnaE intein where the Cys1 was mutated to 
Ala.
[52b]
 In this work, Martin et al. had also suggested that a non-covalent interaction occurred 
between the intein halves.
[52b]
 
For cell surface splicing with mutant construct 4, N2a cells were transfected with expression 
construct 1. 24 h later, protein trans-splicing was performed on the cell surface with protein 4 
(VS18; ST-EGFP-NpuC1SDnaE
N
) which contained the Cys1Ser mutation at the N-terminal 
splice junction. The splicing reaction was performed under the reaction conditions described 
earlier in section 3.3.5. The cells were visualized by confocal microscopy. Green fluorescence 
was detected on the surface of the transfected cells as seen in Figure 30B. Thus, no difference 
was detected in the fluorescence pattern of the wild type construct and the mutants indicative 
of intein association in all three cases. 
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A        B 
 
Figure 30 Protein trans-splicing using splice mutant 4. A) Schematic representation of the protein 
trans-splicing reaction on the cell surface using splice mutant 4. In this construct the first amino acid 
at the N-terminus of the intein, Cys, was mutated to Ser by site directed mutagenesis. B) Confocal 
microscopy images of the splice mutant (red channel) and the reaction with protein 2 (green channel). 
SP = splice product 
 
Validation of splice product formation however necessitates an immunoblot analysis (Figure 
31). The immunoblot performed with the anti-GFP antibody showed low yields of splice 
product formation in the case of the Cys+1Ser splice mutant in comparison to the wild type 
plasmid and was in accordance with the data obtained for the in vitro assay.
[49b]
 This could be 
due to the lower rate of trans-splicing as was reported earlier.
[141]
 An increase in N-terminal 
hydrolysis does occur, however, since this hydrolysis product (ST-EGFP) would be in the 
growth media, it was not observed on the western blot of the cell lysates. In contrast to the 
Cys+1Ser mutant, which showed splice product formation, no product formation was detected 
for the Cys1Ser mutant. This led to the conclusion that similar to the Cys1Ala mutant, the 
intein fragments only associated non-covalently but this complex fell apart when treated with 
SDS containing buffer and boiled at 95 ºC. 
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Figure 31 Anti-GFP western blot showing the effect of various mutations on the splicing 
reaction. Cells were transfected with the relevant plasmid and trans-splicing was carried out. They 
were lysed after washing and western blot analysis was performed with the cell lysate. Lane 1: Cells 
transfected with cytoplasmic mCherry-N1 and reacted with protein 2, Lane 2: Cells transfected with 
construct 1 but no splicing reaction was carried out, Lane 3: Positive control with cells transfected 
with construct 1 and reacted with protein 2, Lane 4: Cells were transfected with mutant construct 3 and 
reacted with protein 2, Lane 5: Cells transfected with construct 1 and reacted with protein 4. SP = 
splice product; M = marker 
 
Thus, the data generated above validated the specificity of the PTS reaction on the cell 
surface. For further characterization of the PTS reaction on the cell surface and for advanced 
applications of this technique, a series of experiments were additionally carried out as 
described from section 4.5 onwards. 
 
4.5 Monitoring the Cell Surface Splicing over a Time Course 
A useful labeling strategy should ideally work with extremely short handling times because it 
reduces the stress on the living sample as well as increases the time for subsequent 
experiments. The studies so far using an intein for the extracellular modification of a 
membrane protein involved artificially split semi-synthetic inteins and reported reaction times 
of several hours which is unsuitable for most labeling reactions.
[90c]
 The Npu DnaE intein was 
shown to possess the highest reported rate for the PTS reaction with a t1/2 of 60 sec.
[49b]
 
However, this was demonstrated in vitro with purified proteins and might significantly vary 
when the same reaction is carried out on the surface of living cells in the presence of 
numerous other cell surface molecules (for, e.g. glycoproteins). Therefore, to assess the speed 
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of the PTS reaction on cell surface, splice product formation was monitored overt 60 min after 
the addition of protein 2. Samples were collected by lysing cells at various intervals with 
SDS-loading buffer and immunoblot analysis was performed. The cell lysate was blotted both 
against anti-GFP (Figure 32A) and anti-HA (Figure 32B) antibodies. 
Splice product (SP 1+2) formation was observed after an incubation of only 5 min and 
increased over time. This observation was supported by the anti-HA western blot which 
showed a gradual decrease in the amount of 1 due to the cleavage of HA-Int
C
 by PTS. These 
results suggested that a nearly complete conversion of 1 into the splice product takes place.  
A       B 
      Anti-EGFP             Anti-HA 
 
Figure 32 Time dependent splice product formation on Neuro-2a cell surface. Neuro-2a cells 
transfected with construct 1 were reacted with protein 2 for varying lengths of time. After each time 
point, the cells were washed and lysed by adding 2x SDS containing buffer and further processed for 
immunblotting. A) Anti-GFP western blot showing increase in splice product formation over time and 
corresponding decrease of starting material, protein 2. B) Anti-HA western blot showing loss of the 
HA-tag during the time course due to the PTS reaction. SP = splice product 
 
Thus, it can be concluded from the above mentioned data that PTS on the cell surface 
proceeds at a considerably fast rate (slower than with purified proteins) making this technique 
suitable for labeling of membrane proteins requiring short handling times. 
 
4.6 Effect of Reducing Agents on the Splicing Reaction 
The first amino acid of the Int
N
-fragment of the Npu DnaE intein is a Cys which is essential 
for the initiation of the splicing reaction and for N-terminal cleavage.
[32d]
 The C-extein Cys+1 
acts as a nucleophile during the trans-splicing reaction, attacking the linear thioester to form 
the branched intermediate (see introduction 1.2.2). These catalytically important cysteines are 
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exposed to the extracellular side of the cell membrane which could lead to oxidation of either 
or both these cysteines. In order to ensure reduced intein fragments, DTT was added at a 
concentration of 2 mM to the reaction mixture routinely. However, this may lead to reduction 
of disulfide bridges of other cell surface proteins, resulting in structural and functional 
changes. Therefore, it was important to characterize the trans-splicing reaction in the absence 
of this additional DTT. 
It was known from in vitro assays using purified proteins in splice buffer that the absence of 
DTT completely abolished protein splicing.
[49b]
 In order to rule out any possible effects of a 
change in buffer (proteins present as a solution in PBS) or the growth media (used for cell 
surface splicing), similar assays were performed with purified proteins using either PBS 
(Figure 33A and B) or serum free DMEM (Figure 33C and D). Protein 5 (VS01; NpuDnaE
C
-
Trx-His6) and protein 2 were added to the reaction mixture at a concentration of 15 µM, either 
in the presence or absence of 2 mM DTT and the splice reactions were analysed via SDS-
PAGE. 
In a separate assay, non-reduced protein 5 was reacted with reduced protein 2 in the absence 
of DTT (Figure 33E). It should be noted here that the Int
C
-fusion protein underwent 
proteolysis within the Int
C
 part upon cell lysis and therefore cell lysis was performed in the 
presence of buffer containing 8 M urea and followed by Ni
2+
-NTA purification under 
denaturing conditions.
[49b]
 The protein could be refolded by a simple dialysis step against PBS 
buffer. 
Similar results were obtained for the splice reaction in PBS and DMEM as in the presence of 
splice buffer dismissing any effects due to the media. Efficient trans-splicing was observed in 
both cases with 2 mM DTT and no trans-splicing was detected in the total absence of DTT. 
The rate at which the splice product formation occurred was slightly lower in the case where 
DMEM was used as the buffer. However, splice product was observed in the case where 
protein 2 was reduced and the excess DTT was removed by dialysis and the reaction was 
carried out in the absence of DTT and non-reduced protein 5. 
Encouraged by the above mentioned results the trans-splicing reaction was further performed 
under the same conditions on the surface of the cells. Neuro-2a cells were transfected with 
construct 1 and the splicing reaction was carried out as described above.  
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A      B 
  PBS+DTT     PBS 
 
C      D 
  DMEM+DTT     DMEM 
 
E 
     DMEM (pre-reduced) 
 
Figure 33 Effect of various buffer conditions on the splicing reaction. Protein 2 and Protein 5 were 
reacted at equimolar concentrations of 15 µM in vitro over a time span of 2 h at 37 °C. The reaction 
was followed by SDS-gel analysis. Samples were taken at various time points by adding 2x SDS 
sample buffer to stop the reaction. A) PTS in PBS buffer with 2 mM DTT. B) PTS under non-reduced 
condition with PBS. C) Splicing reaction in DMEM buffer with 2 mM DTT. D) Splicing reaction 
under non-reduced condition in DMEM. E) Splicing carried out in the absence of DTT but with 
reduced protein 2. M = marker; SP = splice product 
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Microscopy data (Figure 34A and B) and immunoblot (Figure 34C) were consistent with the 
in vitro results obtained with purified proteins. Green fluorescence from the EGFP was clearly 
visible on the surface of transfected cells reacted with the reduced protein 2 as seen earlier 
with cells reacted in the presence of DTT. Partly background fluorescence was observed for 
cells reacted in the total absence of DTT.  
A           B 
      Splicing    Control 
 
C 
 
Figure 34 Effect of DTT on the splicing reaction. The splicing reaction was carried out on the 
surface of cells in the absence of DTT. Protein 2 was reduced and the excess DTT was removed by 
dialysis against PBS buffer and the reaction was performed as earlier. A) Confocal image of neuro-2a 
cells transfected with 1 and reacted with reduced 2. B) Cells transfected with 1 and reacted with non-
reduced protein 2 in the complete absence of DTT. C) Anti-GFP western blot of the trans-splicing 
reaction. SP = splice product 
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For the western blot, the band corresponding to the splice product formation was seen in cell 
lysates where the reaction had either occurred in the presence of 2 mM DTT or with reduced 
protein 2. This band was not seen in lysates where DTT was completely removed.  
These results indicated that no exposure of the cells to reducing agents was necessary and that 
the splicing reaction can be performed if exogenously added intein fusion proteins were 
reduced prior to the assay. This is advantageous as it will prevent reduction of disulfide bonds 
of other cell surface proteins present. The minimum requirement could be the presence of one 
partner protein in its reduced form. 
 
4.7 Effect of the C-Extein Sequence on Cell Surface Splicing 
The present work was targeted at directly labeling the backbone of a cell surface protein. In 
order to achieve that, one needs to be able to go as close to the membrane as possible. A Trx 
domain in the Int
C
 fusion construct was introduced as part of an earlier work involving in 
vitro study of the Npu DnaE intein.
[49b]
 It enhances protein folding and solubility. 
Nonetheless, being a part of the C-extein sequence it is incorporated along with the N-extein 
modification onto the membrane protein. The splicing efficiency was extremely high in this 
scenario; however the extra Trx was not desirable. 
In order to overcome this drawback for future applications, an expression plasmid was 
designed where the Trx sequence was entirely removed. Construct 6 (pTD058; Igκ-HA-
NpuDnaE
C
-myc-TMD-mCherry) was transfected and the expression pattern was observed. 
Fluorescence microscopy revealed that in contrast to the wild type plasmid, this protein was 
highly misfolded and subcellular mislocalization occurred Figure 35A and B. Only small 
amounts of the expressed protein was localized to the plasma membrane as can be seen from 
the immunofluorescence images. 
 PTS was performed on the surface of neuro-2a cells expressing construct 6. The scheme of 
protein trans-splicing along with the calculated weights of the reactants and products is 
shown in Figure 35C and D. Intensity of the EGFP fluorescence observed after trans-splicing 
with protein 2 on the surface of cells transfected with construct 6 was very low and required 
an increased laser power (Figure 35E).  
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The above results pointed towards the fact that the highly soluble Trx domain might somehow 
be responsible for the correct expression and targeting of the entire fusion protein and it 
assisted the Int
C
 terminal half in proper folding. Also, the distance of the Int
C
 half from the 
transmembrane domain/ plasma membrane might be a crucial factor in the protein attaining a 
properly folded conformation.  
A              B  
   Non-permeabilized   Permeabilized 
         
C       D 
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Figure 35 Protein Trans-splicing with the Trx domain removed from the C-terminal fusion 
protein. Immunostaining was performed against the HA-tag using Alexa-fluor 488 labeled secondary 
antibody to observe expression and targeting of construct 6. Neuro-2a cells were transfected with 
construct 6 and fixed 24 h later. Cells were either A) non-permeabilized or B) permeabilized with 
Triton X-100. C) Schematic representation of the trans-splicing reaction on cell surface with fusion 
proteins 6 and 2. D) Calculated molecular weights of the reactants and products of the PTS reaction. 
E) Confocal image of cells transfected with construct 6 and reacted with purified protein 2 observed at 
~5x higher laser power than earlier in both the red and green channel. SP = splice product  
 
In order to circumvent the solubility issue another small and soluble protein, gpD, 
(bacteriophage lambda head protein D) was fused to the N-terminus of Int
C
 in construct 6 to 
generate expression plasmid 7 (pTD061; Igκ-HA-gpD-NpuDnaEC-myc-TMD-mCherry). gpD 
has been used as a fusion partner for high level expression of soluble heterologous proteins in 
E.coli.
[142]
 Several mammalian proteins have been produced by fusion to its C-terminus. It is 
thought to mediate optimal translation initiation while reducing inclusion body formation and 
protein degradation. Being fused N-terminally to the Int
C
 terminal half in the fusion protein, it 
will be fully removed during the reaction and will not be included as part of the cell surface 
display.  
Neuro-2a cells were transfected with expression plasmid 7 and the expression pattern was 
followed by immunofluorescence and confocal microscopy (Figure 36A and B). Indeed, 
fusion of gpD rescued to some extent the misfolding and the mislocalization of the fusion 
protein. However, in comparison to construct 1, the intensity of the fluorescence observed on 
the cell surface was much lower. The majority of the expressed protein was still misfolded 
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and was correlating to the subcellular compartments involved in the secretory pathway. The 
schematic representation and the fusion constructs involved in the PTS reaction along with 
the molecular weights of the reactants and products is illustrated in Figure 36C and D. 
Confocal microscopy analysis of the cell surface PTS with protein 2 revealed low intensity 
EGFP fluorescence requiring high laser power (Figure 36E).  
A         B 
               Non-permeabilized         Permeabilized 
 
C             D 
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Figure 36 Protein Trans-splicing with gpD fused at the N-terminus of the Int
C
 sequence. Cells 
were transfected with construct 7 and fixed 24 h later. Immunostaining was performed against the HA-
tag using Alexa-fluor 488 labeled secondary antibody. Cells were either A) non- permeabilized or B) 
permeabilized with Triton X-100. C) Schematic representation of the trans-splicing reaction with 
construct 7 and protein 2. D) Calculated molecular weights of the reactants and products of the PTS 
reaction. E) Confocal image of cells transfected with construct 7 and reacted with purified protein 2 
observed at ~5x higher laser power than with wild type construct. SP = splice product  
 
A comparison between the expression patterns of construct 1, construct 6 and construct 7 is 
shown in Figure 37A. Majority of protein 1 appears to be targeted to the plasma membrane 
although minor amounts were also visualized in the subcellular compartments. In contrast to 
this, bulk of protein 6 was aggregated in the intracellular compartments with negligible 
amounts present on the membrane. The expression pattern of protein 7 indicates a rescue of 
the protein 6 phenotype. This protein was observed to be targeted to the plasma membrane; 
however, this rescue was only partial as can be observed from the western blot data in Figure 
37 B and C. 
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A 
 
B      C 
 
Figure 37 Comparison of PTS performed with varying Int
C
-fusion proteins. A) Confocal images 
after exogenous addition of protein 2 to cells expressing various Int
C
-fusion proteins. B) Anti-GFP 
western blot showing a comparison of the PTS reaction and product formation for construct 1 and 
construct 6 with protein 2. C) Anti-GFP western blot showing a comparison of the PTS reaction and 
product formation for construct 1 and construct 7 with protein 2. SP = splice product 
 
Western blot analysis was performed with cells transfected with either construct 1, 6 or 7 and 
the splicing reaction was carried out with protein 2. Cells lysates were prepared after addition 
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of SDS loading buffer for stopping the reaction. In accordance with the above mentioned 
fluorescence microscopy pattern observed, the western blot analysis showed no splice product 
formation in case of PTS performed with construct 6 and protein 2. Also, no splice product 
band was observed when the PTS was performed with construct 7 and protein 2 even though 
fluorescence microscopy indicated the targeting of protein 7 to the plasma membrane. This 
could be due to the low amount of this protein available on the extracellular side of the 
membrane. Thus, splice product formation might be occurring in the latter case but it may be 
below detection limit.  
 
4.8 Protein Splicing with Decreased Protein Concentration 
The Int
N
-terminal half fusion protein 2 was used at a concentration of 5 µM in our 
experimental strategy. Inspite of most of the protein being involved in protein splicing, a 
comparable amount of residual protein was observed in the western blot analysis after protein 
trans-splicing and after washing of the cells as mentioned in section 4.1.3. This residual 
protein could be accounted for by unspecific binding and was undesirable.  
In order to resolve this issue, an attempt at decreasing this residual protein band was 
performed by improvising upon the wash conditions. PTS was performed by transfecting 
constructing 1 and adding protein 2 as described earlier. Post splicing, either harder washes 
were performed with normal wash media or 50 U/ml heparin was added to the wash media 
before washing steps were performed. Washing cells harder resulted in the cells getting 
detached from the plate. The cells were then subsequently pelleted by centrifugation and the 
supernatant was removed. The cells were again re-suspended in wash buffer and a second 
centrifugation and supernatant removal steps were performed. Finally, the cells were 
suspended in 100 µl of 2x SDS containing buffer. 
A second attempt at reducing this residual protein band was made by lowering the 
concentration of protein 2 in the splicing reaction. No detectable difference in fluorescence 
intensity was observed in confocal microscopy analysis when the concentration of protein 2 
was lowered from 5 µM to 2 µM (Figure 38A and B). Green fluorescence was clearly 
visualized on the cell membrane of neuro-2a cells transfected with construct 1 and reacted 
with 2 µM protein 2. 
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Western blot analysis from the experiments performed above indicated that lower protein 
concentrations of protein 2 and harder washing indeed decreased the residual band of protein 
2 (Figure 39). This residual protein band was also observed even in the case where no cells 
were plated but the Int
N
 fusion protein was added. This pointed towards the fact that at least a 
fraction of the residual protein 2 was un-specifically attached to the cells or to the plates. It is 
thus possible that all of the background observed was a consequence of this unspecific 
binding, although the possibility that some protein 2 was taken up by the cells by endocytosis 
could not be ruled out. 
A         B 
   Splicing    Control 
 
Figure 38 Confocal images of splicing with a lowered protein concentration. Cells were 
transfected with construct 1 and PTS was performed with 2 µM of protein 2 as described earlier in 
section 3.3.5. Cells were washed and fixed and microscopy analysis was performed. A) Microscopy 
image of cells transfected with construct 1 and reacted with protein 2. B) Controls cells transfected 
with plasmid mCherry-N1 and reacted with protein 2. 
 
The important result which was obtained from these experiments was that the splicing 
reaction could be performed with protein 2 at only 2 µM concentration with no observable 
loss of splice product formation. This is indeed beneficial where yield of the recombinant Int
N
 
fusion proteins is low.  
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Figure 39 Anti-GFP western blot showing control experiments for removal of excess protein 2 
after protein trans-splicing. These experiments were performed to address the cause for the residual 
protein 2 that can be seen in the western blot analysis after protein trans-splicing and after washing of 
the cells. For heparin wash conditions, heparin (50 U/ml) was added to the wash media. For harder 
wash conditions, cells were washed during the second wash until they detached from the plate; cells 
were then subsequently pelleted by centrifugation and the supernatant removed. Lanes 1 & 2: protein 2 
at 5 µM with normal wash conditions; lane 3: no cells with protein 2 at 5 µM with normal wash 
conditions; lanes 4 & 5: protein 2 at 5 µM with heparin wash conditions; lanes 6 & 7: protein 2 at 
5 µM with harder wash conditions; lanes 8 & 10: protein 2 at 2 µM with normal wash conditions; lane 
9: blank; lanes 11 & 12: protein 2 at 2 µM with heparin wash conditions. SP = splice product 
 
4.9 Protein Splicing on the Surface of COS-7 and CHO Cells 
Protein trans-splicing could be efficiently performed on the surface of Neuro-2a cells. 
However, to show the generality of our approach, it was important to show that this labeling 
technique could be universally performed and was not limited to a particular cell type. For 
this reason, splice reactions under conditions similar to those performed on Neuro-2a cells 
mentioned earlier in section 3.5.5 were carried out on the surface of Chinese hamster ovary 
(CHO) and COS-7 cells, two commonly used laboratory cell lines. 
Results obtained from confocal microscopy are shown in Figure 40A for CHO cells and 
Figure 40B for COS-7 cells. EGFP green fluorescence was clearly visualized on the surface 
of cells transfected and expressing protein 1. Thus, the PTS reaction was not dependent and is 
not partial to a given cell type and can be efficiently performed on the surface of different cell 
lines. As the culture conditions for CHO and COS-7 requires a different growth media, the 
PTS reaction was performed in the serum free media of the specific cell type, i.e. HAM‟s-F12 
for CHO and DMEM for COS-7. Similar results were obtained in each case.  
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         CHO           COS-7 
 
Figure 40 Protein trans-splicing on the surface of various mammalian cells. Cells were transfected 
with construct 1 and PTS was performed by addition 5 µM protein 2 as described earlier in section 
3.3.5. Confocal microscopy images were taken post washing and fixation. A) Microscopy image of 
PTS performed on the surface of Chinese hamster ovary (CHO) cells. B) Microscopy image of PTS 
performed on the surface of COS-7 cells. 
 
Thus, this technique is advantageous as it can be applied to various cell lines and under 
various media and buffer conditions as per experimental requirement. 
 
4.10 Protein Splicing Using Various N-exteins 
A good labeling/modification strategy should be amenable to labeling by various functional 
moieties. This would allow for its diverse applications. The PTS reaction in the experimental 
strategy mentioned in this work so far involved direct observation of fluorescence post 
splicing with protein 2 due to EGFP being the N-extein sequence. Therefore, it was 
imperative to study the PTS on the cell surface by replacing the EGFP sequence with a 
different POI.  
To this end, we constructed and expressed a non-fluorescent recombinant fusion protein 
replacing the N-extein EGFP with the maltose binding protein (MBP). MBP is used to 
increase the solubility of recombinant proteins expressed in E.coli which assists in 
purification of the fusion protein. MBP can itself be used as an affinity tag for purification of 
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recombinant proteins. This fusion protein binds to amylose columns while all other proteins 
flow through. The MBP protein fusion can be purified by eluting the column with maltose.  
Construct 8 (TD060; MBP-NpuDnaE
N
-His6) was expressed recombinantly in E.coli.and 
purified via affinity column purification using MBP as the affinity tag. Purified protein 8 
(~56 kDa) was obtained at a very high concentration and was diluted to the appropriate 
concentration before use (Figure 41A and B). In vitro splicing was performed with construct 
9 (AU07; NpuDnaE
C
-EGFP-His6) as the Int
C
 fusion protein in order to show splicing activity 
with purified proteins. 
Construct 9 has EGFP as its C-extein; however, this recombinant protein is very unstable and 
undergoes degradation during protein expression in E.coli. and could not be obtained as a 
single purified band even when purified under denaturing conditions. Therefore, degradation 
bands from this protein purification were also observed on the SDS-PAGE analysis of the in 
vitro splice reaction (Figure 41C). Protein splicing was carried out using 5 µM of protein 8 
and 10 µm of protein 9 and the splicing proceeded efficiently with the splice product band 
(~70 kDa) observed after 5 min of incubation at 37 ºC. 
A       B     C 
 
Figure 41 Characterization of protein 8 with MBP as the N-extein. A) SDS-PAGE analysis of 
recombinant protein expression in E.coli. Protein expression was induced with 0.4 mM IPTG. 
 B) Purification of protein TD060 via amylose affinity chromatography. Protein was eluted with 
amylose elution buffer containing 10 mM Maltose. The protein was obtained in pure form and 
dialysed against PBS buffer. C) In vitro trans-splicing of protein 8 with protein 9 followed on an SDS-
PAGE gel. Splice product formation at the calculated height of 71.4 kDa was observed after 5 min of 
incubation. Protein 9 = NpuDnaE
C
-EGFP-His6; BI = before induction; AI = after induction; P = pellet; 
F.T. = flow through; SP = splice product; M = marker 
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As protein 8 was splice active, PTS was further performed on the cell surface (see Figure 
42A). Scheme of the PTS reaction between protein 1 and protein 8 is shown in Figure 42B. 
Neuro-2a cells were transfected with expression plasmid 1 and incubated with 5 µM of 
protein 8 under the same reaction conditions mentioned earlier in section 3.5.5. However, 
following incubation with the Int
N
-fusion protein, washing and fixation, direct fluorescence 
was not possible due to MBP being a non-fluorescent protein. In order to overcome this 
limitation and based on the understanding that the protein trans-splicing reaction would result 
in the MBP being covalently ligated to the C-extein sequence on the cell surface of Neuro-2a 
cells, immunofluorescence was performed using an anti-MBP primary antibody as described 
in the methods section 3.3.4. Alexa-fluor 488 labeled secondary antibody was used for 
detecting the ligated MBP and confocal microscopy was performed.  
It was clear from the microcopy data obtained that MBP was present on the membrane of 
neuro-2a cells (Figure 42C). To confirm splice product formation, western blot analysis was 
carried out with anti-MBP antibody. The splice product band of the correct size of 90.6 kDa 
was observed on the blot (Figure 42D). However, a second high intensity band was also 
observed which could be a degradation band from the splice product. 
An additional experiment was performed using gpD as the N-extein. Protein 10 (AU08; ST-
gpD-NpuDnaE
N
) was recombinantly expressed in E.coli purified via strep-tag II affinity 
chromatography and dialyzed against PBS buffer. The schematic representation of the 
reaction carried out the cell surface is shown in Figure 43A. Neuro-2a cells were transfected 
with construct 1 and reacted with 5 µM of protein 10. The reaction scheme with calculated 
molecular weights of the proteins and splice product is shown in Figure 43B.  
For a direct comparison of the three constructs 2, 8 and 10 with EGFP, MBP and gpD as the 
N-exteins respectively, a western blot analysis was performed using the c-myc antibody. The 
c-myc tag is present just after the Trx domain in construct 1 and will be retained in the splice 
product. The results from this western blot are shown in Figure 44. 
The band observed at ~55 kDa corresponded to expressed protein 1. The splice product bands 
were observed at their calculated molecular weights in each case. However, the difference in 
the intensity of the SP band could either be due to the difference in the efficiency of the 
reaction as a consequence of the N-extein used or due to improper loading of the sample. In 
support of the former argument, it is known from earlier published data that the overall splice 
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product yield reduces to 50 % when EGFP was used as the N-extein in comparison to gpD. A 
second low intensity band was observed below the SP band in the reaction with MBP as N-
extein hinting at SP degradation.  
A       B   
 
C            D 
 
Figure 42 PTS on the surface of neuro-2a cells with MBP as the N-extein. A) Schematic 
representation of the protein trans-splicing reaction performed on the surface of neuro-2a cells. 
B) PTS reaction of protein 1 with protein 8 and splice product formation with their calculated 
molecular weights. C) Confocal microscopy image of the PTS reaction carried out on the surface of 
neuro-2a cells. Following PTS, the cells were washed and fixed. Immunofluorescence was performed 
using mouse anti-MBP antibody. Detection was carried out by Alexa-488 labeled goat-anti mouse 
antibody. D) Anti-MBP western blot showing bands at the calculated molecular weight of protein 8 
at~56 kDa and SP at ~91 kDa. The additional band observed might be the result of SP degradation. SP 
= splice product 
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Figure 43 Schematic representation of the PTS with gpD as the N-extein. A) Scheme of the 
reaction on cell surface with protein 10 being exogenously added. B) PTS reaction with the calculated 
molecular weights of the fusion proteins involved and the expected splice product. 
 
Figure 44 Trans-splicing using various N-exteins. Neuro-2a cells were transfected with construct 1 
and the PTS reaction was carried out using recombinant fusion proteins with varying N-exteins. Post 
splicing the cells were washed and lysed by the addition of 2x SDS-loading buffer and further 
processed for analysis by western blot using anti-myc antibody. SP = splice product 
 
Thus, PTS on the cell surface can be efficiently performed with various N-extein sequences 
thereby allowing a variety of modifications to be performed on membrane proteins. 
 
4.11 Expression and Targeting of the Int
N
 Fusion Protein 
In the PTS technique described in this work, the Int
C
-terminal half of the intein is fused to a 
POI and expressed in mammalian cells. This Int
C
-fusion protein is then amenable to protein 
modification by various N-exteins fused to the Int
N
-terminal half of the Npu DnaE intein. 
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However, this limits the application of this technique to membrane proteins with their N-
terminal sequence on the extracellular surface. In order to widen its usage to also include 
membrane proteins with their C-terminal sequence on the outside of the plasma membrane, 
the PTS reaction required a switching of the intein partners.  
As proof of principle for the above mentioned approach, EGFP fused to the N-terminus of the 
Int
N
-terminal half of the Npu DnaE intein was constructed as a cell surface protein (construct 
11; pTD020; Igκ-HA-ST-EGFP-NpuDnaEN-myc-TMD). gpD fused to the C-terminus of the 
Int
C
 terminal half of the intein when recombinantly expressed in E.coli and exogenously 
added to the cell surface would result in EGFP being removed due to the PTS reaction. 
However, in this case the splice product will be found in the reaction media. 
To this end, construct 11 was transfected and expressed on the surface of neuro-2a cells. The 
expression pattern of this protein could be directly followed by fluorescence microscopy due 
to the presence of the EGFP at the N-terminus of the cell surface fusion protein. 
Immunostaining was performed with a primary antibody against the HA-tag and an Alexa-
568 tagged secondary antibody as performed earlier in section 3.3.4 to show targeting to the 
plasma membrane and the results are shown in Figure 45A and B. A combination of the 
direct EGFP fluorescence observed and immunostaining microscopy images point towards the 
fact that majority of this protein is present in the subcellular compartments and very small 
amount is actually available on the cell surface. This might be due to an improper folding of 
the Int
N
-fusion protein due to the presence of the 102 aa long Int
N
 domain. 
Nevertheless, in the experimental setup for PTS, construct 11 was transfected into neuro-2a 
cells. 24h post transfection, cells were reacted with protein 12, washed and fixed for image 
acquisition. The scheme of this reaction is depicted in Figure 45C and D. Confocal 
microscopy analysis did not indicate any significant decrease in the EGFP fluorescence due to 
the loss of EGFP in the PTS reaction (data not shown). For detecting splice product formation 
a western blot analysis was also performed as shown in Figure 45E. A sample from the 
supernatant post PTS was taken for identifying the removed EGFP. Corresponding to this 
removal, a decrease in the intensity of the detected protein 11 band should occur in 
comparison to the negative control. However, no splice product band was detected on the 
anti-EGFP western blot. Moreover, no significant decrease of the initial protein 11 band was 
observed either.  
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       Non-permeabilized    Permeabilized 
 
C        D 
 
E 
 
Figure 45 PTS reaction with the Int
N
 fusion protein expressed on the surface of neuro-2a cells. 
Cells expressing protein 11 were fixed and immunostained with Alexa-fluor 568 tagged antibody 
against the surface exposed HA-tag. Cells were either A) non-permeabilized or B) permeabilized with 
Triton X-100. C) Schematic representation of the PTS reaction on the surface of cells. D) Schematic 
representation of the constructs involved in the PTS reaction and the splice product formed. Calculated 
molecular weights of the proteins are given. E) Anti-EGFP western blot for the PTS reaction between 
protein 11 and 12. SP = splice product 
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Therefore, the results obtained from these experiments indicate that only a negligible amount 
of the Int
N
 fusion protein is actually available at the cell surface for a successful PTS reaction 
to take place possibly because of the incomplete fold of the Int
N
 fragment resulting in 
proteolysis in the secretory pathway. 
 
4.12 Protein Trans-Splicing Using GPI Anchored Fusion Proteins 
GPI anchored proteins are localized to the plasma membrane of eucaryotic cells and carry out 
several important functions.
[143]
 A GPI anchor is a post translational modification that is 
added to the C-terminus of proteins and anchors the modified protein in the outer leaflet of the 
cell membrane. A GPI transamidase catalyzes the transfer of a preformed glycolipid anchor to 
substrate proteins that possess an appropriate C-terminal GPI signal sequence. This 
modification occurs in the endoplasmic reticulum and subsequent translocation of the protein 
to the plasma membrane takes place, where the proteins are attached via the anchor.
[144]
 GPI 
biosynthesis pathway is conserved from mammals to protozoa and is carried out in the ER. 
Post translational modification with transamidase complex loads the proteins with synthesized 
GPI precursors. These proteins bearing the GPI precursors in their carboxyl terminals are 
transported to the Golgi complex where the GPI moiety is further subjected to modifications 
and the protein is then finally inserted into the plasma membrane as mature GPI-anchored 
proteins.
[144-145]
  
The importance of these GPI anchored proteins cannot be underestimated judging by the fact 
that approximately 0.5 % of proteins are modified with a GPI-anchor and loss or absence of 
this anchor is usually lethal. Diminished biosynthesis of the GPI anchor due to a genetic 
mutation leads to haemolytic anemia in humans.
[146]
 Loss of GPI anchoring is embryonic 
lethal in mammals
[143b]
 and creates conditional lethality in yeast.
[147]
  
Therefore, going by the significance of these GPI-anchored proteins, their modification by 
protein trans-splicing will be a powerful tool for several biotechnological applications. To 
this end, the transmembrane domain and mCherry sequences from construct 1 were replaced 
with the GPI anchor-recognition motif of the Gas1p sequence from yeast to yield construct 13 
(pTD057; Igκ-HA-NpuDnaEC-Trx-His6-myc-Gas1p). The Gas1p is a glycoprotein anchored 
to the outer leaflet of the plasma membrane through a glycosylphosphatidylinositol and plays 
a key role in cell wall assembly.
[148]
 This Gas1p protein from Saccharomyces cerevisiae is 
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synthesized as a precursor with a hydrophobic extension at the carboxyl terminus. It is 
removed and replaced with an inositol containing glycolipid that anchors the protein to the 
plasma membrane.
[149]
 
Proof of principle experiments required the expression and targeting of construct 13 to the 
plasma membrane and its precise anchoring with a GPI anchor. The recombinantly expressed 
intein fusion partner is added exogenously on the cell surface during the PTS reaction. This 
would result in modification of the POI. As the fusion protein 13 was non-fluorescent, direct 
observation by fluorescence microscopy was not possible. For this purpose, immunostaining 
was performed against the HA-tag present C-terminally to the Igκ leader sequence. Cells 
transfected with construct 13 were fixed 24 h post transfection and reacted with mouse anti-
HA primary antibody and detected with Alexa fluor-488 labeled goat anti-mouse secondary 
antibody. Cytoplasmic mCherry-N1 was co-transfected as a control. Microscopy analysis 
shown in Figure 46A and Figure 46B confirmed the expression of protein 13 and assumption 
of its correct processing and attachment to the membrane with a GPI-anchor was made due to 
the presence of significant amounts of this protein at the plasma membrane. 
Modification of this GPI-anchored protein was carried out by performing PTS on the surface 
of neuro-2a cells. Schematic representation of this reaction is shown in Figure 46C and D. 
Construct 13 was co-transfected with cytoplasmic mCherry into neuro-2a cells. 24 h later, 
PTS was performed on the cell surface by adding the Int
N
 recombinant fusion protein 2. 
Visualization of green fluorescence on the surface of transfected cells post washing and 
fixation indicated the successful completion of the PTS reaction as shown in Figure 46E.The 
splice product formation was further confirmed by western blot analysis performed against 
the anti-GFP antibody. Splice product band was clearly observed at the calculated height of 
~48 kDa as seen in Figure 46F. 
Presently only a few techniques are known to modify a POI with a natural GPI anchor and 
most GPI anchor mimics only represent significantly simplified analogs. To get access to a 
native GPI anchor, Schumacher et al. utilized the yeast post-translational protein modification 
machinery for the production of a protein, which can be used for the C-terminal GPI-
modification of any protein of interest.
[150]
 TEV protease cleavage of the expressed and 
purified protein from yeast cells resulted in a peptide comprising of the C-terminal GPI 
anchor and N-terminal Cys. They used a covalent capture strategy for purifiying and 
enriching the GPI-anchored peptide. This modified peptide can further be ligated with a POI 
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consisting of a C-terminal thioester resulting in a GPI anchored modified protein by using the 
NCL strategy. 
Using the technique presented in this work, one can modify any POI with a native GPI anchor 
and study its properties. For this puropose, the prion protein was used as the model protein 
because so far the expression yield and the isolation of the GPI-anchored protein from cells is 
not efficient enough to get enough protein to study its biochemical behavior. To this end, in 
collaboration with Dr.Miria Schumacher and Prof.Martin Engelhard, EGFP was replaced with 
the prion protein sequence Prp and the recombinant protein was isolated from yeast. However, 
the addition of this protein on the surface of mammalian cell expressing construct 13 resulted 
in cell death (data not shown). The apparent reason could be the toxicity of the prion protein. 
Therefore, a different model protein is necessary.  
A         B 
          Non-permeabilized     Permeabilized 
        
C                                                              D  
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Figure 46 Expression and targeting of GPI-anchored fusion protein. Cells expressing protein 13 
were fixed and immunostained with Alexa-fluor 488 tagged antibody against the surface exposed HA-
tag. Cells were either A) non-permeabilized or B) permeabilized with Triton X-100. Cytoplasmic 
mCherry was co-transfected as transfection control.Schematic representation of the PTS reaction on 
the surface of cells with a GPI-anchored POI. C&D) Schematic representation of the PTS reaction 
between protein 13 and protein 2 with calculated molecular weights of the starting material and splice 
product. E) Neuro-2a cells were co-transfected with construct 13 and cytoplasmic mCherry-N1. 
Protein 2 was exogenously added on the cell surface. After 1h cells were washed, fixed and observed 
via confocal microscopy. F) Anti-EGFP western blot for confirmation of splice product formation at 
the calculated molecular weight. SP = splice product 
 
Nevertheless, these results demonstrate that a GPI-anchored protein can be site-specifically 
and efficiently modified via the protein trans-splicing reaction.  
 
4.13 PCP-Labeling of Cell Surface Proteins with PTS 
 
Fusion of a PCP domain would enable modification with a variety of organic dyes and small 
molecules. Labeling of a POI fused to the PCP domain has been earlier reported by various 
groups.
[126]
 This was based on the promiscuity of the Bacillus subtilis phosphopantetheinyl 
transferase Sfp
[151]
 for loading chemically synthesized peptidyl-CoA substrates onto apo-PCP 
instead of coenzyme A(CoA-SH).
[152]
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For the current work, the PCP domain was cloned from the TycA gene from Bacillus brevis 
ATCC 8185.
[56]
 TycA is one of three peptide synthetases of a large enzyme complex involved 
in the production of the cyclic decapeptide antibiotic tyrocidine produced by via non-
ribosomal peptide synthesis (NRPS).
[153]
 The PCP domain was fused to the N-terminus of the 
Int
N
-terminal fragment to form construct 14. This construct was expressed in E.coli and 
purified via affinity chromatography as shown in Figure 47A. Prior to performing PTS, the 
PCP domain was labeled either with CoA-maleimide derivatized Dylight 488 or TMR. The 
labeling procedure has been described in the methods section 3.2.6. For confirming splice 
activity, in vitro splicing was performed with protein 5 and the reaction was followed on an 
SDS-PAGE and the results obtained are shown below (Figure 47B). Before addition of the 
coomassie staining solution, the gel was visualized under a UV-transilluminator.  
A 
 
B 
 
 
Figure 47 PCP-labeling strategy for labeling cell surface proteins via PTS. A) Schematic 
representation of the in vitro splicing reaction with the relevant molecular weights of the reactants and 
the splice product. Protein purification of construct 14. B) In vitro splicing reaction between protein 5 
and labeled protein 14 followed on an SDS-PAGE over time. Lane 1= protein 5; Lane 2 = protein 14; 
Lane 3 = Labeled protein 14. The right panel shows the magnified form of a part of the gel. Upper half 
of left panel: Grayscale false color of the gel, Lower half: Fluorescence image of the SDS gel. 
P = Pellet; F.T. = Flow Through; M = Marker; E = Elution; SP = splice product  
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Protein yields of construct 14 were very low. Bacterial expression levels and solubility of this 
fusion protein seemed unaffected by the general conditions used in the lab for protein 
expression as mentioned earlier in the methods section 3.2.6. Poor quality of the strep tag 
material was therefore the reason for the low yields of the protein obtained. Furthermore, the 
labeling reaction did not go to completion as can be seen from the occurrence of two bands at 
~25 kDa in lane 3. Nevertheless, splice product formation was observed after 5 min 
incubation as seen under UV-light. This band was also observed in the coomassie stained gel. 
Due to the extremely low concentration of protein 14, the yield of the splice product was also 
minute. An extra unaccounted for band of ~30 kDa was observed throughout the reaction. 
Molecular weight analysis revealed this to be the 27 kDa Sfp PPTase. This was expected as 
the molecular mass of Sfp is greater that the cut of limit of the dialysis tube used.  
This experimental section proves that a labeled PCP domain is active in PTS and can further 
be used for labeling of cell surface proteins.  
 
4.14 Detecting Protein-Protein Interactions Using FCCS and PTS 
 
Zamir et al. have devised an elegant approach for studying protein-protein interactions in 
living cells using the FCCS approach.
[154]
 They have used quantum dots as small bait 
recruiting surfaces that can be microinjected into cells expressing fluorescently tagged prey 
proteins. Their strategy involved coupling of the quantum dot to recruiting agents such as 
antibodies or peptides that bind endogenous bait proteins with high specificity and high 
affinity. However, this would require protein specific expensive antibodies or synthesis of 
specific peptides. One way of overcoming this drawback would be via the intein based 
method earlier discussed.  
This intriguing concept has been outlined in the figure given below (Figure 48). The Int
C
 
terminal fragment is fused at the N-terminus of either a PCP domain
[56]
 or a Cys tag
[92a]
 (C-
extein). PCP can further be labeled with biotin-CoA via the Sfp-catalyzed reaction.
[155]
 Biotin 
can also be conjugated to the Cys tag via maleimide chemistry.
[156]
 This biotinylated fusion 
protein when incubated with streptavidin coated quantum dots gets labeled with these 
nanoparticles via the high affinity streptavidin-biotin interaction.
[157]
 The bait protein (N-
extein) fused to the Int
N 
terminal fragment when reacted with the Int
C
 fusion protein thus gets 
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labeled with fluorescent quantum dots by the protein trans-splicing mechanism. This would 
allow the in vitro coupling of any protein of interest to quantum dots.  
 
 
Figure 48 Schematic representation for labeling a POI with quantum dots for FCCS. In the first 
step the Int
C
-PCP fusion protein is biotinylated at a specific serine residue via the Sfp PPTase method. 
In the second step streptavidin coated quantum dots are conjugated to the fusion protein by the biotin-
streptavidin mediated interaction. The last step involves PTS with a POI fused to the N-terminus of the 
Int
N
 terminal half of the split intein. Removal of the intein halves results in a POI labeled with a Q.D. 
 
For proof of principle experiments, PCP fused to the C-terminus of the intein C-terminal 
fragment (construct 15) was recombinantly expressed in bacteria and purified. The protein 
underwent proteolysis within the Int
C
 part upon cell lysis and therefore cell lysis was 
performed by the addition of buffer containing 8 M urea (Figure 49A). The protein was 
finally obtained in a pure form in high concentrations and dialyzed against PBS buffer. Test 
for splicing activity was carried out in vitro both with protein 2 and protein 10. Prior to 
splicing protein 15 was labeled either with Co-A derivatized TMR or Dylight 488 via the Sfp 
labeling
[155]
 method described earlier in the methods section 3.2.6. Equimolar concentrations 
of each protein was added to the reaction mixture and the reaction was followed on an SDS-
PAGE. The reaction was carried out in PBS buffer under 2 mM DTT conditions and the 
results obtained are shown in Figure 49B. This work was carried out together with diploma 
student Christina Kantzer.
[138]
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Figure 49 In vitro splice activity test for Int
C
-PCP fusion construct. A) Schematic representation of 
the splicing reaction performed in vitro using two different N-extein fusion proteins along with the 
relevant molecular weights of the reactants and splice products. The extreme right image depicts the 
protein purification of protein 15 under denaturing conditions. B) Upper panel: SDS-PAGE analysis of 
the splice product reaction. Grayscale and UV images of the PTS reaction of protein 15 with protein 
10.Lane 1: Protein 10; Lane 2: Labeled protein 15; Lane 3: Protein 15. Lower panel: Grayscale and 
UV images of the PTS reaction of protein 15 with protein 2. Lane 1: Protein 2; Lane 2: Labeled 
protein 15. Equimolar concentrations of the purified proteins were used in each case. 
 
Protein 15 was obtained in a purified form in high yields. Splice product formation was 
observed after an incubation period of 5 min with the two different N-extein sequences. 
However, the yield of the splice product was higher in the case of gpD as the N-extein in 
comparison to the EGFP. This was in accordance with earlier reported data.
[49b]
 C-terminal 
cleavage as a side product of the PTS reaction was also observed in each case. The splice 
product was not clearly visible in the coomassie stained gel due to the small mass difference 
between protein 2 (40.8 kDa) and the SP (40.2 kDa). However, it was clearly observed in the 
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UV-illuminated gel as only the SP will be labeled in this case. An extra band at ~30 kDa was 
observed in each case which corresponded to the mass of the Sfp PPTase. Thus, a successful 
PTS reaction could be performed with a PCP labeled protein as the C-extein and this protein 
can further be used for labeling with other CoA-derivatives. According to the earlier designed 
strategy (Figure 48), the next step would involve labeling of this PCP fusion protein with 
CoA derivatized with biotin. 
Prior to modification of the Int
C
 construct with biotin, control experiments were required with 
streptavidin quantum dots QD-655 (red emission) to rule out any unspecific binding of the N-
terminal intein fragment. EGFP was used as the bait protein in this scenario as a partner 
fluorescent protein. 500 nM EGFP-Int
N
 was incubated with 20 nM of Q.D‟s at 37 °C for 15 
min to 30 min and washes were carried out with PBS with a centrifugal filter column (YM-
100) to remove excess/unbound EGFP-Int
N
 protein and the interaction was followed by FCCS 
analysis. In a separate experiment, incubation was carried out for the same time period at R.T.  
FCCS measurements were carried out on a LSM-510 ConfoCor 3 (Zeiss) using a 40x water 
immersion objective. Samples were excited with a 488 nm laser line (SW-FCCS) and 
fluorescence emission was split by a dichroic mirror NFT 565 and detected using a 505-610 
nm band-pass and a 655 nm long-pass filter for the green and red channel detection. The line 
trace of the FCCS data and the correlation curves obtained are shown below (Figure 50 and 
Figure 51). 
A smooth cross-correlation curve with an average cross-correlation value G(t) > 1 is 
considered significant A significant cross-correlation curve was obtained when incubation 
was performed at 37 °C between Int
N
-terminal fusion protein and QD 655 [G(t) < 2] (Figure 
50B). The preliminary data obtained showed no cross-correlation [G(t) ≤ 1] where incubation 
was carried out at R.T. (Figure 51). Only a noise signal was obtained in this scenario. This 
assumption was made based on the lack of simultaneous fluctuations in the red and the green 
channel. Only individual auto-correlation curves were obtained in each case. This led us to 
believe that the reaction maybe temperature dependent and at higher temperatures there is 
greater unspecific binding taking place between the quantum dots and the split intein fusion 
protein. A further control experiment with only EGFP reacted with QD‟s yielded a similar 
result. A high cross-correlation value [G(t) > 1] was obtained when EGFP was incubated with 
the quantum dots at 37 °C. This was further proof of unspecific binding at higher 
temperatures 
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The intensity of the QD is much higher than EGFP as is clearly seen. Quantum dots were 
incubated at R.T. with increasing concentrations of protein EGFP-Int
N
 (500nM-2µM) in order 
to further verify the absence of cross-correlation between the two molecules. The number of 
EGFP molecules was extremely low as was expected. However, with increasing 
concentrations of the fusion protein, the number of molecules in the GFP channel was also 
observed to increase. This could be due to the fact that as similar numbers of washes were 
performed in each case, larger number of GFP molecules were retained in the column when a 
higher concentration of the fusion protein was used. Nevertheless, no cross-correlation was 
observed with the fusion protein even at 2 µM concentration. Further experiments with the 
Int
C
 fusion protein will have to be performed. The strategy outlined above can in principle be 
performed with both artificially and naturally split inteins. However, artificially split inteins 
aggregate or misfold and may also require higher concentrations of the fusion protein giving 
rise to false cross-correlation signal. This was apparent from the FCCS analysis performed 
under similar conditions as described above using the Mxe GyrA intein (Figure 50A). The 
Mxe GyrA artificially split intein showed high cross-correlation value [G(t) ~ 1.2] at a 
temperature of 25 °C. 
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A         B 
 Q.D. + Mxe GyrA
N
 (25 °C)    Q.D. + Npu DnaE
N
 (37 °C) 
 
C 
Q.D. + GFP (37 °C)  
 
Figure 50 Control experiment for studying non-specific binding of Q.D.655 to EGFP-Int
N
. 
Control experiments were performed to rule out non-specific binding of the EGFP-Int
N
 fragment to 
Q.D‟s lacking the IntC fragment. The graph shows the average cross correlation between the two 
molecules over time. The height of the peak corresponds to the intensity of the fluctuations. 
Fluctuations arise when a fluorescent molecule passes the small observation volume. Simultaneous 
fluctuations of both fluorescent molecules determines the degree of binding. Blue curve: EGFP auto-
correlation; Red curve: Q.D auto-correlation; Black curve: cross-correlation  
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A          
               Q.D. + Npu DnaE
N
 (R.T.)  
     Cross-correlation curve     
  
B 
Auto-correlation curve 
 
Figure 51 Control experiment for studying interaction of Q.D. 655 with EGFP-Int
N
 at R.T. 
20 nM Q.D. were reacted with 500 nM of protein EGFP-Int
N
. Washing was performed to remove 
excess protein. FCCS was performed to assess the degree of bound GFP molecules. A) Cross-
correlation curve between Q.D and EGFP-Int
N
. B) Auto-correlation curves of Q.D (Right upper panel) 
and EGFP-Int
N
 (Right lower panel). Blue curve: EGFP auto-correlation; Red curve: Q.D auto-
correlation; Black curve: cross-correlation  
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Figure 52 Effect of increasing EGFP-Int
N
 concentration. Q.D. 655 were incubated with increasing 
concentrations of EGFP-Int
N
 at R.T. FCCS measurements were carried out using the Zeiss confocor. 
Count rates vs time graphs are plotted here. With increasing concentrations the number of GFP 
molecules were also found to increase in the focal volume but there was no significant cross-
correlation curve was obtained. Blue curve: EGFP auto-correlation; Red curve: Q.D auto-correlation; 
Black curve: cross-correlation  
 
The technique reported here will not only be useful for studying protein protein interactions 
but will also enable PTS on the surface of quantum dots resulting in labeling of any POI with 
these inorganice nanocrystals. Intein mediated site-specific conjugation of QD‟s to proteins 
has been reported earlier.
[78]
 The authors synthesized the Int
C
 terminal half of a split intein via 
SPPS and performed in vitro conjugation of Int
C
-biotin to streptavidin coated quantum dots. 
In another case quantum dot nanosensors for detecting protease activity were created by 
intein-mediated specific bioconjugation and detected by bioluminescence resonance energy 
transfer (BRET).
[158]
 Quantum dot conjugation to proteins via the split intein mediated 
approach will additionally add to the repertoire of fluorescent techniques and widen 
biotechnological applications. 
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5 DISCUSSION and FUTURE OUTLOOK 
 
5.1 On Various Labeling Strategies for Cell Surface Protein Modification 
 
Chemical modifications of proteins can be accomplished by various techniques such as total 
chemical synthesis
[159]
, enzyme mediated reactions
[2a]
, nonsense suppression mutagenesis
[160]
 
and a variety of bioconjugation
[161]
 and protein ligation methods.
[162]
 These modifications 
provide the ability to site-specifically incorporate a range of chemical probes such as 
fluorescent molecules, photocrosslinkers, unnatural amino acids and are invaluable tools for 
studying cellular living systems. Consequently, development of strategies that enable the 
specific modification of proteins in cellular contexts is an area of immense interest in 
chemical biology. Proteins on the surface of cells have been of particular interest for this 
purpose because not only do they play a significant role in relaying extracellular signals, in 
transport etc. but also because their structure and function is affected markedly due to the 
dynamic nature of the plasma membrane. They play a central role in various biological 
processes and are important drug targets. Numerous cell surface protein labeling strategies 
have been developed (see section 1.3) with each approach having its own advantage and 
limitations and no one approach is suitable for every POI. Therefore, the demand for more 
tools is ever increasing.  
Most of the labeling methods developed so far rely on the development of a tag for the 
specific labeling by a probe which equips the protein of interest with a new functionality.
[2b]
 
They require several other features like high specificity, small tag, no toxicity, no perturbation 
of the target protein, versatility in the choice of available fluorophores, a short labeling time 
etc. These features are often incompatible with each other and there is often a trade-off 
between specificity and size. For e.g. labeling using a hAGT fusion involves the use of a 
~20 kDa protein that may compromise biological function of the protein of interest due to its 
size.
[163]
 In contrast, PTS is traceless and results in the autocatalytic removal of the intein 
fragments. Chemical modification of the smaller ACP/PCP fusions
[126a]
 or tags for biotin 
ligase
[164]
 and lipoic acid ligase
[122]
 require the addition of the conjugation enzyme next to the 
actual synthetic molecule. Furthermore, these methods result only in the attachment of a 
modified prosthetic group to a particular side chain in the tag and are thus not suitable to 
directly manipulate the peptide backbone structure of the POI. PTS, however, can be used for 
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manipulating the structure and primary sequence of membrane proteins. The sortase mediated 
ligation
[130c]
 method does allow for the backbone engineering of proteins but the reaction 
requires high concentrations of both the substrates and the enzyme Sortase A. PTS, in 
contrast, does not necessitate an extra enzyme as the protein trans-splicing is a self-processing 
reaction.
[27b, 165]
  
Most of the techniques for cell surface labeling developed so far are very specific for labeling 
membrane proteins which is desirable in most instances. Their applicability to internal 
proteins is however restricted due to several reasons. One major cause for this is the 
difference in the extra-(oxidising) and intra-(reducing) cellular environment. The tetracysteine 
system
[105]
, for e.g., requires a reducing environment. PTS with known naturally split inteins 
progresses efficiently in an intracellular environment due to the presence of catalytic 
cysteines.
[166]
 This might be a drawback for labeling proteins in the extracellular region as it 
will lead to oxidation of the conserved cysteines. This might be overcome by using a different 
intein lacking a catalytic cysteine residue at the +1 position, e.g. the Mxe GyrA
[42]
 and Tli-
Pol2 inteins
[167]
 have a +1Thr at this position and the Ssp GyrB intein
[5b]
 and Psp GBD Pol
[86]
 
have a Ser+1. However, applications of these to the cell surface labeling method discussed in 
this work would require artificial splitting which might further lead to insolubility problems. 
Moreover, splicing activity may be considerably affected. 
PTS in an intracellular environment would be unlikely in the absence of both the intein 
halves. However, techniques like the tetracysteine system
[105]
, the Texas Red binding peptide 
system
[168]
 suffer from background labeling. Other techniques like the biotin ligase/lipoic acid 
ligase, ACP/PCP labeling are restricted to labeling proteins present only on the cell surface 
due to the requirements of the labeling strategy. Moreover, the biotin ligase method requires 
millimolar concentrations of the probes to achieve significant labeling. PTS on the other hand 
has been demonstrated to occur at low micromolar concentrations for labeling both intra-
[166]
 
and extra-cellular
[4]
 proteins.  
Since the majority of the techniques mentioned here require genetic fusions to 
peptide/proteins, their expression, folding, localization or functions may alter. Large fusion 
partners, that possess localization signals and highly charged fusion partners often alter the 
function of the target protein. A flexible linker region may reduce chances of altering the 
functions of a POI. The tetracysteine and biotin ligase system are preferred in this regard.  
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Therefore, it is evident that different strategies are required for labeling different cell surface 
proteins and no unique system is applicable to them.  
 
5.2 On PTS as a Suitable Method for Labeling Cell Surface Proteins 
 
In the present work we have succeeded in labeling cell surface proteins by the split intein 
mediated method of protein trans-splicing. The strategy for labeling cell surface proteins 
using PTS, although described earlier, has never been reported using a naturally split intein. 
Earlier work by Ando et al.
[90c]
 and Volkmann et al.
[90a]
 demonstrated cell surface protein 
labeling utilizing the semisynthetic approach (see section 1.3b).
[165a]
  
Ando et al. performed extracellular modification of a membrane protein on the surface of 
CHO cells using the artificially split semi synthetic Ssp DnaB intein where a reaction time of 
8 h was reported. Moreover, affinity between the split partners was very low (requiring over 
10 µM reactant concentrations) and an integration of the receptor-ligand interaction between 
eDHFR and its ligand trimethoprim was required for conferring high affinity in order to 
perform the labeling reaction. The artificially split Ssp DnaB intein consists of a small 11aa 
N-intein and a large C-intein
[39, 46]
 and thus was not suitable for labeling proteins with their C-
terminus facing the extracellular surface. Volkmann et al. took advantage of the Ssp GyrB 
split intein consisting of a very small C-intein (6aa) and a large 150 aa N-intein
[47]
 for labeling 
the transferrin receptor on the surface of CHO cells. This method was however carried out 
over 18 h and was applicable for labeling only the C-terminus of cell surface proteins. In 
contrast, incubation time of only 5 min was sufficient in this work for modifying a cell 
surface protein using the Npu DnaE intein and within 1 h the reaction was almost complete. It 
was clear from the time lapse experiment performed (Figure 32) that the splice product 
formation was very fast. However, in comparison to the in vitro reaction with purified 
proteins where the proteins are well separated, freely accessible and not influenced by other 
biological factors
[49b]
, the reaction on the cell surface proceeds at a slower rate. Different 
experimental conditions (DMEM media instead of the standardized splice buffer) and the 
presence of other extracellular proteins on the cell surface may further impede the reaction. 
Therefore, it is evident that the major advantage conferred by PTS using a naturally split 
intein method over semi-synthetic trans-splicing reaction is the speed of the modification. 
However, this may be greatly affected by the choice of the intein. In an earlier report, the Int
C
 
terminal fragment of the Ssp DnaE intein was synthesized semi-synthetically and used to label 
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an intracellular POI.
[166]
 However, an incubation of 3 h was reported here. Zettler et al. 
reported a t1/2 of ~60s for the Npu DnaE intein using purified proteins which is 33 to 170 fold 
higher than the rate reported for the Ssp DnaE intein.
[49b]
 A second advantage would be the 
concentrations of the reactants required in each case. PTS demonstrated so far with artificially 
split inteins require peptide concentrations in the higher micromolar range. The present study 
was able to show successful labeling with a protein concentration of only 2 µM which is 
much lower in comparison to the existing methods.  
Since a naturally split intein has evolved to splice together two halves, the intein fragments 
are expected to behave better in terms of folding and solubility. Artificially split inteins often 
suffer from protein aggregation problems due to the exposure of hydrophobic patches on the 
surface and often require a protein denaturation and renaturation step. This might prove to be 
detrimental for sensitive proteins.
[165a]
  
Shorter labeling times is advantageous for membrane protein labeling as it will allow for a 
longer visualization time before the labeled protein is internalized by endocytosis. 
Additionally, use of photolabile moieties requires short handling and data analysis time.  
 
5.3 On Cell Surface Protein Modification Using the Npu DnaE Intein 
 
I. Choice of the intein 
In this work the naturally split Npu DnaE intein from Nostoc punctiforme has been used for 
labeling cell surface proteins. This intein was chosen based on various criteria discussed 
below. Iwai and co-workers had demonstrated the robust trans-splicing activity of this intein 
with non-native exteins in E.coli.
[3]
 It was shown to possess > 98 % ligation efficiency and 
20-fold less residual precursor proteins in comparison to the Ssp DnaE intein. Further, Zettler 
et al. had determined an apparent first order rate constant of (1.1±0.2) x10
-2
 s
-1
 at 37 ºC for 
this intein using purified proteins
[49b]
 which is 5.5 fold higher than the rate reported for the Sce 
VMA intein and 33 to 170 fold higher than the Ssp DnaE intein and is by far the highest rate 
reported for the PTS reaction. Thus, it was a very suitable choice for fast and efficient 
modification of proteins expressed on living mammalian cells (see also section 1.2.2). 
The reasons for the superior properties of this intein is as of yet not clearly understood as it is 
highly homologous to the Ssp DnaE intein but still displays a remarkable difference in 
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splicing activity. All conserved amino acid known to be essential for the catalytic function are 
identical in both cases. The Ssp DnaE
N
 fragment has a C-terminal extension of 21 aa lacking 
in Npu DnaE intein which is not part of the intein structural fold.
[43d]
 The Npu DnaE and the 
Ssp DnaE inteins have also been shown to cross-react, however the rate reported for the Npu 
DnaE intein was only possible in the native combination of the inteins.  
One could possibly think of extending the applications of the Npu DnaE naturally split intein 
by further performing semi-synthetic trans-splicing. The Int
C
 (36 aa) has been synthesized by 
solid phase peptide synthesis for covalently modifying target proteins with lipid anchor 
peptides.
[169]
 A shortened functional C-intein that still retains its robust splicing activity was 
designed by Aranko et al. with the engineered intein bearing the C-terminal 15aa of the C-
intein and 123 aa long Int
N
.
[45]
 The ligation efficiency of this new intein was ~96 % and it was 
shown to improve protein ligation by accelerating the PTS reaction. The kinetic constants for 
the trans-splicing reaction were estimated to be 4.8 ± 0.3 x 10
-5
 s
-1
 in the presence of 0.5 mM 
TCEP. The split site of the engineered intein is located in the loop between β12 and β13 of the 
Npu DnaE intein structure. Oeemig et al. solved the NMR structure of a single chain variant 
of Npu DnaE intein (see Figure 51).
[43b]
 They further engineered a C-intein half consisting of 
only 6 aa which was efficient in PTS. 
 
Figure 53 NMR structure of a single chain variant of Npu DnaE intein. Ribbon diagram of the 
crystal structure of the Npu DnaE intein solved by Oeemig et al.
[43b]
 PDB ID = 2KEQ 
 
A second problem that could restrict the application of this intein is the C-terminal junction 
containing the canonical „CFN‟ tripeptide sequence which remains in the product after 
splicing thereby resulting in a mutant protein of interest.
[49]
 It is currently unclear why this 
sequence is required for efficient PTS. The critical catalytic activity of this C-extein cysteine 
residue also limits its usage in the cysteine bioconjugation reaction (see section 1.3b) although 
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the Int
C
- half in itself is free of any cysteine residues. However, PTS still occurs although at a 
compromised rate when this Cys is mutated to a Ser. The yield of the reaction is unaffected. 
 
II. Specificity 
A strong and highly specific interaction between the split intein halves is suggested from the 
demonstrations (Figure 39) that the split inteins were able to splice in the presence of several 
other extracellular proteins even at low micromolar concentrations. This is because split 
inteins are under evolutionary pressure to associate rapidly with high fidelity and dissociate 
slowly post-splicing as they splice together essential gene fragments in an endogenous 
environment, for e.g., proteins involved in DNA replication and formation of unproductive 
complexes would be deleterious to the survival of the cell.  
Despite the broad utility of the PTS reaction, little is known about what drives this highly 
efficient association of split intein fragments.
[49a]
 Ionic interactions have been postulated to 
play a role in this split intein assembly.
[44, 49a]
 These studies revealed segregation of charges at 
specific residues of the intein fragments. Acidic residues were concentrated at specific 
positions on the N-intein and basic residues dominated the C-intein and these charged 
residues participate in intermolecular ion-pair interactions.
[43b]
 This was also found to be more 
prevalent in naturally split inteins. The experimental realization of this hypothesis has been 
recently carried out by Shah et al. where the authors performed charge swapping experiments 
between the inteins to probe the role of intermolecular ion-pair interactions and in the process 
also designed a new mutant intein which displayed low cross reactivity with the wild type 
intein.
[170]
 This further allowed the authors to perform one-pot three piece fragment ligation.  
The high efficiency of the PTS reaction on the cell surface at a concentration of only 2 µM 
was most likely a result of this high affinity and fast association of the split intein fragments. 
For the same reason, ruling out the possibility of only an associated complex and no splicing 
due to this affinity was extremely important in this study. This interaction was strong enough 
to survive simple washing steps and specific enough as to abolish splicing with splice 
mutants. Both wild type and the splice mutants showed interactions between the inteins in the 
microscopy study post washing steps. The difference was revealed only on western blot 
analysis where the complex is believed to break apart due to the loss of the non-covalent 
interactions by boiling. This was in accordance with earlier reports with the Ssp DnaE 
intein.
[52a]
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The extra band observed in the immunoblot data of Figure 28 was assigned as the starting 
material band by molecular weight analysis. Decrease of this residual protein band when 
lower concentrations of protein were used and/or harder wash conditions were applied hinted 
at unspecific binding to the cells or to the 6-well plate. This could be due to the reaction 
conditions used in this study and leaves room for further optimizations of the washing steps. 
Unreacted EGFP-Int
N
 and incomplete washing would also contribute to the signal. However, 
confocal microscopy data, as seen earlier had not shown any significant fluorescence with the 
control expression plasmid (Figure 27C). Hence, it was concluded that this band was more 
pronounced in the western blot simply because of the extremely high sensitivity of this 
detection procedure.  
Previous in vitro work by Zettler et al. reported an almost complete abolition of PTS with the 
Cys+1Ser mutation while the same substitution in the Ssp DnaE intein did not affect the yield 
of the reaction although it reduced the rate of the reaction by a factor of 10.
[49b, 52a]
 The 
authors suggested an altered geometry and/or polarization of the key residues in the active site 
of the inteins as an explanation for a difference in reactivity. A second plausible explanation 
could be the superior folding properties of this intein into its active conformation after 
fragment association. In another study by Yang and coworkers demonstrated that the 
Cys+1Ser mutant was sufficiently splicing active, although it showed slower kinetics in 
comparison to the native cysteine residue.
[158]
 They could successfully perform FRET with a 
dual- colored labeled proteins using this mutant intein. Results obtained with the splice 
mutant for performing PTS on the cell surface (Figure 31) seemed to corroborate these earlier 
observations. The lower yield of splice product could therefore be attributed to a block in the 
transesterification step in the splicing pathway. However, this effect would be more 
pronounced with purified proteins in vitro in comparison to a highly sensitive western blot 
procedure. Thioester cleavage may also occur due to the mercaptoethanol being present in the 
SDS-sample buffer, thereby resulting in N-terminal hydrolysis. Such a product obtained will 
however occur in the supernatant and will be lost during the washing steps prior to cell lysis.  
The Cys1Ala mutant of this intein was reported to completely abolish PTS and was also in 
accordance with the effect observed for the Ssp homologue.
[49b, 52a]
 This could be explained by 
a block in the N-S acyl shift reaction, thereby completely inhibiting the PTS reaction. The C-
terminal cleavage reaction was also shown to be completely blocked and was accounted for 
by the dependence of the asparagine cyclization at the C-terminal splice junction on the acyl 
shift at the N-terminus. The results obtained for the Cys1Ser mutant in Figure 31 could also 
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be similarly explained. In vitro data with this splice mutant showed no splice product 
formation (unpublished data, Schütz et al.) and consistently no splice product was observed 
with the PTS reaction on the cell surface. One might argue that Ser could partially be able to 
substitute as a nucleophile and might result in low amounts of splice product formation. 
However, such an effect was not observed even with the immunoblotting procedure. This 
would highlight the critical nature of the Cys1 residue and would represent an intricately 
evolved balance of chemical reactivities. These data were also consistent with earlier work 
using the Sce VMA1 intein where the Cys1Ser mutant had resulted in a complete loss of the 
protein splicing activity.
[32f]
 
 
III. Effect of reducing agent 
In theory, PTS does not require any thiol reagents for the reaction.
[27c]
 Nevertheless, both the 
splice junctions of the Npu DnaE intein contain unpaired cysteines which in theory could 
form intermolecular disulfide bonds thereby preventing correct association. Therefore, it is 
desirable to keep the reaction under reducing conditions. However, surfaces of cells contain 
numerous proteins and addition of a reducing agent would lead to reduction of disulfide 
bridges of these proteins leading to structural and functional defects. In such a scenario, the 
reduced thiol group of the cysteine of „CFN‟ may interact with erroneous proteins and 
participate in disulfide bond formation. This may however be prevented due to the highly 
specific and very strong affinity between the intein partners. An additional cause may also be 
the relatively low abundance of this amino acid in mammalian proteins.  
Omission of DTT from the reaction assay did not show any significant difference in the PTS 
reaction in vitro and in vivo, as seen from Figure 34, if the exogenous protein was reduced 
prior to the assay and the excess DTT was removed. The catalytic cysteine of the C-extein is 
expected to be in its non-reduced state since it is exposed to the extracellular oxidizing 
environment. However, since free cysteines are unlikely to be available on the extracellular 
environment (only present as disulfides), the thiol group of the „CFN‟ cysteine is unable to 
form disulfide bridges with other cell surface proteins and thus remains in its reduced form. It 
could thus be speculated from previous literature and data obtained from this study that one 
catalytic cysteine in its reduced form is sufficient to drive the PTS reaction. An additional 
consideration would be the concentration of the DTT used in the reaction, as it was previously 
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reported with the Ssp DnaE intein that the presence of 50 mM DTT would almost totally 
block PTS and instead shunt the reaction towards cleavage products.
[45]
 
The type of reducing agent used has been earlier reported to greatly influence the yield of the 
reaction. This is because the thiol group of DTT is a nucleophile competing with the thiol of 
the first cysteine of the C-intein and induces dominant cleavage reactions. Side reactions in 
the presence of TCEP are significantly slower because it has no thiol group. Although one 
might exchange DTT with TCEP in an in vitro reaction; Tris of TCEP would most likely be 
toxic for living cells.
[137]
 
 
IV. Effect of the extein sequences 
PTS was found to be dependent on the protein sequences of the exteins even if the sequences 
around the splicing junctions were identical but how the exteins influence the PTS remains 
unclear. Variation in reaction yields is not only dependent on the intein and the directly 
flanking sequences but also on the N-extein sequence. This was demonstrated with purified 
proteins by Zettler and coworkers.
[49b]
 The authors had reported that this intein tolerated 
varying N-extein sequences with no loss in the reaction rate which was corroborated in the 
present study. A similar trend was observed with the various N-exteins used in this study as is 
seen in Figure 44. However, it is still unclear how the N-extein sequence affects the splicing 
reaction. The size, stability, solubility and folding properties of the N-extein sequence may 
play a critical role in the formation of the active conformation of the Int
N
 sequence required 
for the PTS reaction. The results obtained in the present study (Figure 44) hint at such a 
possibility. The gpD sequence due to its small size, high solubility and an independently 
folding domain is extremely well tolerated and may assist in the correct folding of the entire 
recombinant fusion protein. This was evident from the high expression levels of this protein 
and the near completion of the PTS reaction both in vitro and on the cell surface. The MBP 
sequence although contributes to protein solubility is a rather big protein and may introduce 
structural changes or instability in the fusion protein. The PTS reaction although highly 
efficient on the cell surface also appears to suffer from degradation of the splice product 
which could result from the action of proteases or due to instability caused by the large size of 
the MBP. Reduction of the overall splice product yield to about 50-55 % was reported by 
Zettler et al. on swapping the N-extein to EGFP.
[49b]
 The result obtained in the present study 
was in accordance with the in vitro results. The PCP fusion protein (in vitro) was also 
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effectively able to undergo splicing reaction inspite of a lower concentration of the purified 
protein obtained. The splice product formation at 5 min was a confirmation of the rapidity at 
which PTS occurs. The overall charge of all the N-extein sequences besides PCP used was 
negative (see Table 5), which further ruled out non-specific interactions with the negatively 
charged membrane. The PCP sequence has a net positive charge which might lead to 
unspecific binding of the labeled protein to the plasma membrane resulting in a false positive 
result. This might be a hindrance in performing PTS on the surface of mammalian cells. 
Table 5 Charge of the N-extein sequence at pH 7.0 
N-extein Charge 
Strep-EGFP -5.465 
MBP -10.552 
Strep-gpD -1.584 
Strep-PCP +2.415 
 
V. Protein folding 
Trans membrane domain proteins, regardless of function, are synthesized and assembled in 
the rough endoplasmic reticulum. Proteins destined for translocation into the ER usually 
contain amino terminal signal sequences recognized by a cytosolic ribonucleoprotein 
complex, the signal recognition particle (SRP). A range of ER resident molecular chaperones 
and folding factors that function to assist the folding and oligomeric assembly of the newly 
synthesized protein is encountered by the polypeptide as it enters the lumen of the ER.
[171]
 
Proteins which do not assemble correctly with partner subunits or are unable to reach their 
properly folded state are retained and degraded by an ER „quality control‟ system that 
functions to eliminate such non-functional polypeptides.  
These points are highlighted when one looks at the expression and targeting pattern of the 
various C-exteins used in this study. A plausible explanation for the results obtained in 
Figure 37A could be the correct folding of the C-extein fusion proteins. Trx is a highly 
soluble tag which enhances the folding and solubility of the fusion protein.
[172]
 
Understandably, the loss of this domain resulted in misfolding of the intein fusion protein. 
 Discussion  
113 
Expression levels of the protein appear to be unaffected; however plasma membrane targeting 
is severely impaired. The mCherry fluorescent protein is an autocatalytic domain that folds 
extremely rapidly accounting for the observed red fluorescence. The partial rescue by the gpD 
protein was most likely due to its assistance in folding.  
Fusion of the gpD domain at the N-terminus of the fusion protein, construct 7, was unable to 
completely salvage the protein and redirect it to the plasma membrane in the absence of the 
Trx domain. The reasons for this could only be speculated upon. It could either arise due to 
the gpD not being well tolerated at this position or the inappropriate distance of the Int
C 
split 
intein half from the transmembrane domain. An in vitro reaction with purified proteins might 
be important in further answering this question. If PTS is observed efficiently with the gpD-
Int
C
 fusion protein, this might rule out the possibility of non-tolerance of this sequence at the 
C-terminus of the Int
C 
fragment. 
A confounding observation made in the time lapse experiments was the loss of the HA-tagged 
fusion protein over time. Although the extremely fast PTS reaction could account for the 
gradual loss of the HA epitope from the cell surface protein over time, it did not however 
justify for the fusion protein present in the secretory pathway. This observation can be 
interpreted by assuming the majority of the protein to be present on the cell surface. Another 
possible explanation could be the inaccessibility of the HA epitope due to incomplete folding. 
The fluorescence in the red channel could be due to the cleaved mCherry in the secretory 
pathway and the remaining protein being degraded. The immunofluorescence data (Figure 
26) may provide a justification for these explanations. The intensity of the green fluorescence 
in permeabilized cells was much higher at the plasma membrane than in the subcellular 
compartments for fusion protein 1. Likewise, misfolded proteins resulted in a higher green 
fluorescence in the secretory pathway (Figure 37A). In contrast to the immunofluorescence 
method, the immunoblot technique should however allow access to even denatured proteins 
and therefore the above explanation may not be completely plausible.  
What is evident here is, that the folding state of the protein plays a crucial role in determining 
the targeting, translocation and degradation of the protein. A temporal relationship exists 
between protein translocation, folding and polypeptide chain modification. 
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f. Broad applicability 
The extent of modification can well be influenced by the type of host cell line, the level of 
expression and the physiological status of the cell. This was clearly demonstrated by the 
results obtained with the three different cell lines (N2a, CHO, COS-7) used in this study. The 
N2a cell line was most efficient. Although each cell line grew as a monolayer, the transfection 
efficiency of the N2a cells was highest. This could be due the small circular size of the cell 
which might offer least resistance to transfection. Also, the cell density obtained with this cell 
line was much higher than with the CHO or COS-7 cells where the cells are more flat and 
larger in size. This maybe due to the rapid proliferation rate of the neuro-2a cells (~10 h 
doubling time) in comparison to the COS-7 cells (~18h) and CHO cells (~17h). Thus, this 
might account for the higher number of transfected cells obtained after a 24 h time span in 
neuro-2a cells. 
In theory, the PTS reaction described in this work could be used for labeling both the N-and 
C-terminal cell surface exposed proteins in contrast to the methods adopted by Volkmann 
et al.
[90a]
 and Ando et al.
[90c]
 However, labeling transmembrane proteins with their C-terminal 
end exposed to the extracellular environment would require fusion of the protein of interest to 
the N-terminus of the Int
N
 half and expression of this fusion construct on the extracellular 
surface. A look at the results obtained with this experimental setup, points towards the fact 
that fusion constructs to the Int
N
 terminal half are not as well tolerated as fusions to the Int
C
 
terminal (Figure 45). Presence of the majority of this protein in the secretory pathway 
suggests misfolding. One reason for this could be the large size of the Int
N
 fragment which 
might fold inefficiently with non-natural extein sequences within cellular systems. Protein 
expression of this fusion construct was also suboptimal in a bacterial expression system where 
large amounts of the protein was found in the inclusion bodies. Fusion of small or soluble tag 
proteins (e.g., Trx, gpD, MBP) might offer a solution to this problem.  
Interestingly, the splicing reaction was highly efficient on the cell surface both with a trans 
membrane domain fused protein and a GPI anchored protein. In fact, higher yields were 
obtained for both the expressed protein and the splice product formed with the Int
C
-GPI 
fusion protein (Figure 46). However, a direct comparison of protein expression is not 
possible between construct 2 and 13 since the indirect immunostaining method is much more 
sensitive in contrast to the direct mCherry fluorescence. GPI-anchored proteins are anchored 
to the outer leaflet of the plasma membrane. This may allow better access of the purified Int
N
 
fusion protein to the Int
C
 terminal half exposed on the extracellular surface. The GPI anchored 
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proteins are also processed via the secretory pathway and would explain the fluorescence 
observed in the subcellular compartments. (Figure 46A and B) These proteins have also been 
implicated to exit the ER via a mechanism different for transmembrane proteins.
[173]
 It has 
been postulated that the GPI-anchored proteins partition into sphingolipid-containing „raft‟ 
subdomains in the Golgi and plasma membrane.[174]  
In conclusion we have shown a new method for the fast and efficient modification of cell 
surface proteins on living mammalian cells based on protein trans-splicing at physiological 
temperatures. Due to the autocatalytic character and self removal of the split intein halves, it 
is possible to ligate even entire protein domains with this approach. This approach allows 
direct backbone modification of POI in a post translational fashion. PTS is also a promising 
approach for site-specific labeling of fluorophores in transmembrane regions of membrane 
proteins in living cells, a currently challenging technology. Likewise, the strategy shown here 
will enable a new route to the preparation of proteins modified with a GPI anchor. 
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6 ABBREVIATIONS 
 
 AA     Amino acid 
 Bla     Betalactamase 
 BRET     Bioluminiscence Resonance Energy Transfer 
 CHO     Chinese Hamster Ovary 
 CMV     Cytomegalovirus 
 CoA     Coenzyme A 
 DNA     Deoxyribonucleicacid 
 DTT     1,4-Dithiothreitol 
 E.coli     Escherichia coli 
 EDTA     Ethylenediaminetetraaceticacid 
 EGFP     Enhanced Green Fluorescent Protein 
 EPL     Expressed Protein Ligation 
 ER     Endoplasmic Reticulum 
 FCS     Fluorescence Correlation Spectroscopy 
 FCCS     Fluorescnce Cross-correlation Spectroscopy 
 FKBP     FK506-Binding Protein 
 FRET     Fluorescence Resonance Energy Transfer 
 gpD     Headprotein D of Bacteriophage λ 
 GPI     Glycosylphosphatidylinositol 
 HA     Hemagglutinin 
 His6     Hexahistidine 
 Int
N
     Intein N-terminal half 
 Int
C
     Intein C-terminal half  
 IPTG     β-Isopropylthiogalactoside 
 LB     Luria Bertani 
 MBP     Maltose Binding Protein 
 MW     Molecular Weight 
 Mxe     Mycobacterium xenopi 
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 Npu     Nostoc punctiforme 
 NRPS     Non-ribosomal Peptidesynthesis 
 NTA     Nitrilotriacetate 
 OD     Optical Density 
 ORF     Open Reading Frame 
 PAGE     Polyacrylamide Gel Electrophoresis 
 PCP     Peptidyl Carrier Protein 
 PCR     Polymerase Chain Reaction 
 PDB     Protein Data Bank 
 POI     Protein of Interest 
 Ppant     4‟-phosphopantetheinyl 
 PTS     Protein trans-splicing  
 QD     Quantum Dot 
 rpm     Rotations per minute 
 RNA     Ribonucleicacid 
 RT     Room Temperature 
 Sce     Saccharomyces cerevisiae 
 SDS     Sodium Dodecyl Sulphate 
 SPPS     Solid Phase Peptidesynthesis 
 SRP     Signal Recognition Peptide 
 t1/2     Half-life 
 TCEP     Tris-(2-carboxyethyl)-phosphine 
 TM     Transmembrane 
 TMR     Tetramethylrhodamine 
 Tris     Tris-(hydroxymethyl)-aminomethane 
 t-RNA     Transfer Ribonucleicacid 
 Trx     Thioredoxin 
 UV     Ultra Violet 
 v/v     Volume by Volume 
 w/v     Weight by Volume 
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